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ABSTRACT OF THE DISSERTATION 
 
 
ImmunoPET/fluorescence imaging and radioimmunotherapy 
of PSCA-positive prostate cancer 
 
by 
 
Wen-Ting Katie Tsai 
Doctor of Philosophy in Molecular and Medical Pharmacology 
University of California, Los Angeles, 2018 
Professor Anna Wu Work, Chair 
 
Prostate cancer diagnosis and treatment options need to be improved as over- and under-
treatment, as well as disease recurrence and resistance to current therapies, continue to be 
challenges. Prostate stem cell antigen (PSCA) is overexpressed in the majority of prostate 
cancers and correlates with grade, stage, and metastatic potential. Antibodies, which are 
highly specific for their target, can be labeled with radionuclides and fluorophores for 
molecular imaging and therapy. This dissertation describes the use of humanized anti-PSCA 
antibody fragments for dual-modality immuno-positron emission tomography 
(immunoPET)/fluorescence imaging and for radioimmunotherapy of prostate cancer in 
preclinical models.  
 
Prostate cancer visualization could be improved by using immunoPET for preoperative non-
invasive disease detection, and fluorescence imaging for intraoperative guidance of tumor 
resection; the power of both imaging modalities can be combined on a single agent. In this 
work, the dual-labeled humanized anti-PSCA A11 cys-minibody (A11 cMb) was evaluated 
 iii 
for successive immunoPET/fluorescence imaging in subcutaneous and orthotopic prostate 
cancer models. A11 cMb was site-specifically conjugated with the near-infrared fluorophore 
Cy5.5 and radiolabeled with 124I or 89Zr. 124I- and 89Zr-A11 cMb-Cy5.5 were used to detect 
subcutaneous and intraprostatic PSCA-positive tumors. High contrast 
immunoPET/fluorescence imaging with 124I-A11 cMb-Cy5.5 identified both high PSCA-
expression and moderate PSCA-expression subcutaneous tumors.  89Zr-A11 cMb-Cy5.5 
immunoPET showed uptake in the prostate without interfering signal in the bladder, and ex 
vivo fluorescence imaging clearly showed signal in the tumor and not the surrounding 
seminal vesicles. These studies support the potential for dual-modality A11 cMb to be 
translated for preoperative whole-body disease detection and real-time surgical guidance in 
prostate cancer patients. 
 
Prostate cancer that metastasizes often becomes resistant to current therapies and 
eventually progresses, and alternative therapy options include radioimmunotherapy which 
delivers a high radiation dose to the tumor with the aim of minimizing dose to normal organs. 
Anti-PSCA antibody fragments radiolabeled with a cytotoxic radionuclide, such as the beta-
emitter 131I or 177Lu, may be effective for radioimmunotherapy with lower toxicity compared to 
intact antibodies. 124I- and 89Zr-A11 minibody (A11 Mb) immunoPET was used to guide 
dosimetry studies, and 131I- and 177Lu-A11 Mb was administered to 22Rv1-PSCA s.c. tumor-
bearing nude mice to complete dosimetry estimation. 131I-A11 Mb had a higher projected 
therapeutic index, or tumor-to-radiosensitive tissue dose, and was used in subsequent 
therapy studies. 131I-A11 Mb inhibited PSCA-positive tumor growth in a dose-dependent 
manner and extended survival with minimal off-target toxicity. Additionally, preliminary 
biodistribution studies in knock-in transgenic mice that express human-PSCA were similar to 
that of nude mice. Therefore, radioimmunotherapy will likely not be toxic to organs with 
normal PSCA expression (stomach, bladder), and A11 Mb may be suitable for human 
translation. 
 iv 
 
The results of this work demonstrate the potential of anti-PSCA minibodies as theranostic 
agents for disease diagnosis, surgical guidance, and treatment. Additionally, the success of 
anti-PSCA dual-modality imaging and radioimmunotherapy in preclinical models support 
further evaluation in the clinic. 
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Chapter 1: Introduction 
    1
1 Introduction 
1.1 Overview of prostate cancer 
1.1.1 Prostate cancer epidemiology 
Prostate cancer is the second most diagnosed solid cancer worldwide (1). The most 
significant risk factors are age, race, and family. For example, the incidence in men ages 65 
and older is much higher than ages 20-64, although the advent of prostate specific antigen 
(PSA) screening led to a decline in incidence in the older age groups (Figure 1.1). 
Additionally, incidence in African American men is 60% higher than in white men due to 
aggressiveness and disparities in care (1). Although men with low-risk disease are more 
likely to die with rather than from prostate cancer, progression to metastatic castration 
resistant prostate cancer (mCRPC) is lethal. 
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Figure 1.1 Incidence of prostate cancer. The incidence initially increased after PSA 
screening was adopted in the late 1980s due to over-diagnosis. The implementation of 
active surveillance in the early 1990s led to a decline in incidence, most prominently in men 
ages 65+. Reprinted with permission from Springer Nature (1). 
 
1.1.2 Prostate cancer biology 
Prostate cancer typically develops in the peripheral zone, in contrast to benign prostatic 
hyperplasia which originates from the transitional zone. Prostatic intraepithelial neoplasia 
(PIN) can develop into prostate adenocarcinoma when the androgen receptor (AR), which 
normally binds the androgens testosterone and 5α-dihydrotestosterone (DHT), becomes 
constitutively active. Although androgen deprivation therapy can inhibit or slow tumor growth, 
it is not curative and resistance can occur. Resistance mechanisms include AR gene 
amplification which increases the sensitivity of tumor cells to androgens, AR mutation so that 
it can be activated by other ligands, or splicing variation that allows AR to be constitutively 
produced (2).  
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1.1.3 Prostate cancer diagnosis 
Prostate cancer is typically first suspected after digital rectal exam (DRE) or high levels of 
prostate-specific antigen (PSA). However, patients with benign prostatic hyperplasia and 
other non-cancerous conditions may also have raised PSA levels, and therefore patients 
with PSA levels above 4 ng/mL may receive an accompanying test such as a biopsy. 
Biopsies are performed by taking 10-12 cores with transrectal ultrasound (TRUS) guidance, 
and samples are analyzed using histology. Additionally, the use of multiparametic magnetic 
resonance imaging (mpMRI) overlaid with real-time US allows for targeted biospies of 
suspicious lesions, which was shown to improve diagnosis in two trials (1).  
 
1.1.4 Prostate cancer staging and stratification 
The histological appearance of the biopsies is graded using the Gleason scoring system, 
which describes the likelihood of the disease to spread (Figure 1.2). The score (range 2-10) 
is represented as a sum of two most common patterns (ie 3+4 =7) from the biopsy with the 
highest pattern (3). In 2014, an updated grading system to describe Gleason scores 6-10 
was established by the International Society of Urological Pathology, indicated in Table 1.1 
(4). The clinical stage is based on the tumor, node, metastasis (TNM) system, which refers 
to the extent of disease spread: confined to the primary tumor, spread to regional lymph 
nodes, or metastasized to the rest of the body. Typically, the metastasis pattern begins with 
regional pelvic lymph nodes, spreads next to distant lymph nodes and bone, and finally to 
visceral organs such as liver in advanced disease.  
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Figure 1.2: Gleason grading and scoring system. Reprinted with permission from Springer 
Nature (1). 
 
Table 1.1: Pathologic Grading System of the International Society of Urological Pathology. 
Table based from information in (4). 
 
 
 
Grade Gleason Characteristic 
1 6 (3+3) Well-formed glands 
2 7 (3+4) Predominantly well-formed glands, some poorly formed 
3 7 (4+3) Predominantly poorly formed glands 
4 8 (4+4, 3+5, 5+3) Only poorly formed, fused, or cribiform glands 
5 9, 10 (4+5, 5+4, 5+5) Lacks gland formation 
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Patients are stratified by risk (low, intermediate, and high), which is based on blood levels of 
PSA, Gleason score, and TNM (Table 1.2). Risk stratification can be used to guide staging 
and management, such as the recommendations to use CT/MRI and bone scan imaging for 
intermediate and high-risk patients, or active surveillance for low-risk patients. 
 
Table 1.2: European Association of Urology (EAU) risk groups and recommendations for 
biochemical recurrence of localized and locally advanced prostate cancer. Table adapted 
with permission from (3).  
 
1.1.5 Prostate cancer treatment 
The primary treatment options for men with localized disease are expectant management 
(watchful waiting and active surveillance), surgery (radical prostatectomy), and radiation 
therapy (external-beam radiation therapy, and brachytherapy). After treatment, biochemical 
recurrence (BCR) may occur, which is characterized by rising PSA after therapy, even 
without the presentation of symptoms. If the disease advances, bone scans and imaging 
tests may be conducted to identify the site of BCR and inform the next course of treatment.  
 Any risk Low-risk Intermediate-risk High-risk Locally 
advanced   Localized Localized Localized 
  
PSA < 10 ng/mL 
and GS < 7 
and cT1-2a 
PSA 10–20 ng/mL 
or GS 7 
or cT2b 
PSA > 20 ng/mL 
or GS >7 
or cT2c 
any PSA 
any GS 
cT3–4 or cN+ 
 
Do not use 
CT and 
TRUS for 
local staging 
Do not use 
additional imaging 
for staging 
For metastatic screening, 
include at least cross-
sectional abdominopelvic 
imaging (s.a. CT/MRI) 
and a bone scan for 
staging purposes. For 
local staging, use 
prostate mpMRI (in 
predominantly Gleason 
pattern 4).  
Use prostate mpMRI for local 
staging. Perform metastatic 
screening including at least 
cross-sectional abdominopelvic 
imaging and a bone-scan. 
GS = Gleason score; PSA = prostate-specific antigen; cT = clinical T, based on a physical exam 
or imaging (in contrast to pT, based on pathology of removed prostate). CT = computed 
tomography; mpMRI = multiparametric magnetic resonance imaging; MRI = magnetic 
resonance imaging; PCa = prostate cancer; TRUS = transrectal ultrasound. 
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Metastatic disease is primarily first treated with androgen deprivation therapy (ADT), and 
those with more advanced disease may be treated with both radiation and ADT. Failure to 
respond to ADT results in mCRPC, and many drugs have been evaluated for survival 
extension. For example, the anti-androgens abiraterone or enzalutamide may be given as a 
first-line treatment to mCRPC patients and have been shown to extended survival by a 
median of 18 months, and the chemotherapeutic docetaxel could be offered as second-line 
treatment. These therapies are discussed more in depth in section 1.3. 
 
1.2 Imaging of prostate cancer 
1.2.1 Molecular imaging 
Despite recent advances prostate cancer care, there is a critical demand for improved 
disease detection, staging and stratification. Noninvasive imaging methods, including 
ultrasound, magnetic resonance imaging (MRI), positron emission tomography (PET), and 
single-photon emission computed tomography (SPECT), have been adapted to aid prostate 
cancer diagnosis, and the current FDA-approved molecular imaging probes (indicated in 
Table 1.4) include 99mTc-methylene diphosphonate bone scintigraphy (99mTc-MDP), 111In-
anti-PSMA 7E11 antibody (ProstaScintTM), 18F-sodium fluoride, and 11C-choline. However, 
each of these probes and modalities has its limitations. For example, MRI is a highly 
sensitive and reliable strategy for local staging and identification of soft tissue lesions, but 
may not be sensitive enough to detect lymph node metastases or differentiate from 
inflammation (5). Therefore, the use of more than one imaging probe or modality may 
provide more information on the disease extent to guide treatment decisions. 
 
1.2.2 SPECT imaging of prostate cancer 
99mTc-MDP SPECT is one of the most commonly used methods to detect bone metastases 
through the process of chemisorption, or accumulation at the bone surface. However, 99mTc-
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MDP is limited in the ability to detect micrometastases, and it is not specific for prostate 
cancer (6). Prostate-specific antibodies include anti-PSMA antibody 7E11 (ProstaScint), 
which binds to the intracellular domain of PSMA. Therefore, although approved by the FDA, 
ProstaScint is limited in the ability to image prostate cancer cells with intact membranes. 
Other PSMA-targeting antibodies that bind to the extracellular domain have been developed 
for SPECT imaging, including J591 radiolabeled with 99mTc and with 111In. 111In-J591 SPECT 
showed 94% of the bone lesions detected by conventional CT and bone scans in patients 
with mCRPC (7), and J591 radiolabeled with positron-emitters was also used for PET 
imaging studies. However, as the optimal imaging time point is 5-7 days, J591 derived 
fragments were also evaluated. 99mTc-J591 cys-diabody was used for same-day SPECT 
imaging of mice bearing subcutaneous PSMA-positive prostate carcinoma tumors, and 
specificity was confirmed through blocking studies (8). PSMA-targeted radioligands have 
also been developed as SPECT imaging agents. For example, 99mTc-PSMA I&S was 
recently evaluated as a tool for radioguided surgery to intraoperatively confirm lesions 
detected by presurgical PET imaging, as well as exclude additional lesions (9).    
 
1.2.3 Overview of PET imaging of prostate cancer 
Molecular imaging of prostate cancer by PET has been successful in identifying primary and 
metastatic disease, and it is a powerful tool to guide therapy selection, stratify patients, and 
monitor response to treatment. The most commonly used PET tracer, 2-deoxy-2-[18F]fluoro-
D-glucose (18F-FDG), had limited success in differentiating primary prostate carcinoma from 
hyperplasia due to the low metabolism of most prostate cancer, and therefore other PET  
tracers have been developed and evaluated in preclinical and clinical studies (Table 1.3, 
Figure 1.3). 11C-choline, 18F-fluorocholine, and 11C-acetate are used to image lipogenesis in  
prostate cancer, while the recently approved 18F-fluociclovine (FACBC) targets amino acid  
transport systems (10).  
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Biochemical 
target/mechanism 
Radiopharmaceutical Imaging 
technique 
Bone matrix 99mTc-MDPa 
99mTc-HDPa 
SPECT 
 [18F]Sodium fluoridea PET 
Glucose metabolism [18F]Fluorodeoxyglucose (FDG)a PET 
Lipid metabolism [11C]Choline (CH)a 
[18F]Fluorocholine (FCH) 
[11C]Acetate 
[18F]Fluoroacetate 
PET 
Amino acid transport [11C]Methionine PET 
 [18F]FACBC PET 
Androgen receptor [18F]FDHT PET 
Gastrin-releasing peptide 
receptor (GRPR) 
68Ga-BAY86–7548 
64Cu-CB-TE2A-AR06 
PET 
Prostate-specific 
membrane antigen 
(PSMA)-antibody binding 
111In-capromab pendetide (ProstaScint™)a 
111In-DOTA-J591 mAb 
177Lu-DOTA-J591 mAb 
SPECT 
 89Zr-DFO-J591 mAb 
89Zr-DF-IAB2M (J591 minibody) 
PET 
Small-molecule PSMA 
inhibitors 
99mTc-MIP-1404 
123I-MIP-1095 
Planar/SP
ECT 
 68Ga-PSMA 
68Ga-MIP-1588 
18F-DCFBC 
18F-DCFPyL 
PET 
aFDA approved   
Table 1.3: Radiopharmaceuticals for molecular imaging of prostate cancer. Table reprinted 
with permission from Springer Nature (11). 
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Figure 1.3: Molecular imaging strategies currently applied for prostate cancer. Figure 
reprinted with permission from (6). 
 
1.2.4 Lipid metabolism-based PET imaging 
11C- and 18F-fluorocholine  
11C-choline and 18F-fluorocholine PET are based on the increased use of choline by cancer 
cells due to increased cell proliferation, likely related to the synthesis of phosphotidylcholine 
which is used in cell membrane synthesis. 11C-choline PET was able to differentiate between 
benign and malignant prostate cancer in patients (12), but due to the fast half-life of 11C (20 
minutes), it can only be performed where an on-site cyclotron is available. Choline labeled 
with 18F (t ½ = 110 min) allows for logistical flexibility, and 11C- and 18F-choline have a pooled 
sensitivity and specificity of 86 and 93% for detection of metastases (13). 11C-choline was 
approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with 
suspected recurrence, and the EAU recommends 11C-choline PET/CT for patients with 
biochemical recurrence after radiotherapy (3). 
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11C- and 18F-acetate 
Acetate is typically used in cells as acetyl-coA, and uptake of 11C- and 18F-acetate in 
prostate cancer is likely due to the upregulation of fatty acid synthetase (6). Although 11C-
acetate was found to be highly specific, it also has low sensitivity (68%) and similarity in 
uptake between prostate cancer and benign prostate hyperplasia (BPH) (6). 
 
1.2.5 Amino acid transport-based PET imaging 
18F-fluociclovine 
18F-fluociclovine (FACBC), an analog of the amino acid L-leucine which is transported at a 
higher rate in prostate cancer, was approved by the FDA and European Medicines Agency 
(EMA) in 2016 for detection of recurrent prostate cancer. Compared to 11C-choline, FACBC 
had higher sensitivity and specificity in patients who relapsed after surgery (14). Although 
FACBC uptake can overlap with BPH nodules, one study showed that combination of 
FACBC and MRI reduced the number of false positives and improved positive predictive 
value compared to either modality alone (15). However, another study concluded FACBC 
PET/MRI had low sensitivity for lymph node metastases, and therefore it cannot replace the 
standard staging method (extended pelvic lymph node dissection) (16). 
 
1.2.6 Androgen receptor-based PET imaging 
18F-fluoro-dihydrotestosterone 
The androgen receptor is the main driver of prostate cancer development and progression, 
and 18F-fluoro-dihydrotestosterone (18F-FDHT) PET has been used to assess AR occupancy, 
but it may not be a reliable imaging agent due to the reduction of binding in patients treated 
with antiandrogens. However, 18F-FDHT may potentially be used to optimize doses of 
antiandrogens (11). 
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1.2.7 18F-sodium fluoride 
18F-sodium fluoride (18F-NaF) is an FDA-approved PET imaging agent for bone metastases. 
Similar to diphosphonates, 18F-NaF is taken up by the bone through chemisorption. Although 
it has been largely replaced by 99mTc-MDP, NaF clears more rapidly and results in higher 
contrast (6). A review study reported high sensitivity (89%) and specificity (91%) based on 
pooled data (17), and a prospective study demonstrated 18F-NaF PET was used to detect 
significantly more metastases than PSMA-targeted 18F-DCFBC (see 1.2.10) in patients with 
early and metastatic castrate-sensitive disease (18). 
 
1.2.8 Overview of antigen-specific PET imaging of prostate cancer 
While cell metabolism imaging has been successfully used to detect new lesions in patients 
with biochemical recurrence, the lipid synthesis and amino acid transport processes 
upregulated in prostate cancer can also occur in benign tissues. Therefore, antibodies, 
antibody fragments, and peptides based on targeting prostate cancer biomarkers such as 
prostate-specific membrane antigen (PSMA) (19,20) and gastrin-releasing peptide receptor 
(GRPR) (6,21), have also been developed for PET imaging as well as therapy.  
 
1.2.9 PSMA antibody-based PET imaging  
Prostate specific membrane antigen (PSMA) is overexpressed in local prostate cancer, 
lymph node and bone metastases, and correlates with disease progression and recurrence. 
Antibodies and peptides targeting PSMA have been developed for immunoPET and 
fluorescence imaging (22-24), as well as therapy. Example anti-PSMA antibodies that have 
been evaluated in the clinic include 89Zr-radiolabeled J591 intact antibody and the IAB2M 
minibody. 
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89Zr-J591 
In a Phase I/II study, 50 patients with mCRPC were injected with 89Zr-J591. For detection of 
bone lesions, 89Zr-J591 immunoPET was superior (95% accuracy) to conventional bone 
scintigraphy, CT, and FDG, although detection of soft-tissue lesions (60% accuracy) was 
similar to individual conventional imaging methods. However, due to the longer circulation 
time of intact antibodies, the optimal imaging time point was 6-8 days. Therefore, J591 
derivative antibody fragments were assessed in preclinical models, including IAB2M. 
 
89Zr-IAB2M 
In a preclinical comparison study of 89Zr-anti-PSMA J591 antibody fragments, the minibody 
IAB2M resulted in higher tumor uptake than the diabody and faster clearance than the intact 
antibody (25), and therefore it was developed further in the clinic. In a Phase I first-in human 
study, 89Zr-IAB2M PET detected bone and soft tissues lesions in 17 of 18 patients with 
metastatic prostate cancer by 48 hours, compared to baseline 99mTc-MDP (9 patients) or CT 
(6 patients) to detect bone lesions, or MRI (14 patients) or 18F-FDG PET (10 patients) to 
detect nodes or soft tissue lesions (Figure 4b) (19). Compared to PSMA-targeting peptides 
(see below), little to no uptake was observed in lacrimal and salivary glands, and liver uptake 
was attributed to minibody clearance and residualizing radiometal. The sensitivity and 
specificity of 89Zr-IAB2M will be further assessed in a Phase II trial (NCT03675451), which 
includes comparison to mpMRI and 68Ga-PSMA-11. 
 
1.2.10 PSMA small molecule-based PET imaging  
Small molecule PSMA ligands radiolabeled with 68Ga or 18F have been widely used for PET 
imaging, although they have yet to be approved by the FDA or EMA. These peptide 
mimetics clear rapidly, and those based on the urea backbone have advanced the farthest in 
the clinic. The binding motif is composed of a Glu-urea-Lys motif which targets the catalytic 
domain of PSMA, and linked to a chelator for radiometal labeling (ie 68Ga), or a prosthetic 
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group for 18F-labeling. Although the first PSMA ligands developed for PET were labeled with 
68Ga, 18F has longer half-life which allows for ease of distribution. Additionally, 18F has a 
lower positron energy and therefore leads to better spatial resolution, which may allow for 
improved sensitivity for detection of small tumors. 68Ga-PSMA-11 (HBED-CC), 68Ga-PSMA-
617, 68Ga-PSMA-I&T, 18F-DCFBC, 18F-DCFPyL, and 18F-PSMA 1007 are among the most 
commonly used ligands for PET, typically in patients with biochemical recurrence (26,27). In 
these patients, diagnosis and staging is crucial to treatment planning, and studies have 
shown that PSMA ligand PET informed a change in the therapy plan of 42-75% of patients 
(27).  
 
68Ga-PSMA-11 
PSMA-11 includes a chelator HBED-CC, which can complex with 68Ga. 68Ga-PSMA-11 is 
commonly used in the clinic for imaging patients with biochemical reoccurrence, especially in 
Europe, and several studies have shown it has superior detection rates compared to choline 
(26). Additionally, in patients who are candidates for salvage therapy and have PSA levels 
below 0.5 ng/mL, 68Ga-PSMA-11 has been shown to detect disease at a higher rate than 
other imaging modalities such as 18F-choline (28). However, limitations include the excretion 
of 68Ga-PSMA-11 through the bladder, which may obscure sites of recurrence, and diuretics 
can be used to help visualize the prostate (28). 
 
68Ga-PSMA-617 
PSMA-617 was developed with the binding properties of PSMA-11 and the chelator DOTA in 
order to allow for radiolabeling with trivalent radionuclides 177Lu, 90Y, and 225Ac. PSMA-617 
has been used for PET imaging (68Ga-PSMA-617) as well as radiotherapy (177Lu-PSMA-617) 
(26).  
 
68Ga-PSMA-I&T 
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PSMA-I&T is a theranostic agent that has been radiolabeled with 68Ga for PET imaging, 111In 
for SPECT and radioguided surgery, and 177Lu for radioimmunotherapy (26). In first-in-
human studies, 68Ga-PSMA-I&T detected metastatic lesions with lower activity in 
background organs compared to 68Ga-PSMA-11, although uptake in salivary glands was still 
high (29). In a retrospective study, 68Ga-PSMA-I&T was shown to be effective at guiding 
pretreatment staging in high-grade disease; however, its effectiveness may be limited for 
detecting metastases in patients with Gleason score 7 or less (30). 
 
18F-DCFBC and 18F-DCFPyL 
In metastatic hormone-naïve and mCRPC patients, 18F-DCFBC was shown to be superior in 
lesion detection compared to conventional imaging methods, although liver metastases and 
some bone metastases had low contrast (31). However,  18F-DCFBC results in high 
persistent activity in the blood, which led to the development of the second generation tracer 
18F-DCFPyL for more rapid excretion and superior contrast (28). 
 
18F-PSMA 1007 
PSMA 1007 was designed as a companion diagnostic to 177Lu-PSMA-617 therapy, 
consisting of a scaffold based on PSMA-617 and a prosthetic group for 18F-radiolabeling 
(32). Unlike other PSMA-ligands, 18F-PSMA 1007 clears through the hepatobiliary route with 
minimal urinary excretion, which may be advantageous for visualizing the pelvic region. In a 
retrospective study, 18F-PSMA 1007 detected lesions at a higher rate (62%) than 68Ga-
PSMA-11 (46-58%) in patients with low levels of PSA (0.2-0.5 ng/mL) after radical 
prostatectomy (33).  
 
General imitations to PSMA imaging 
Off-target accumulation of small molecule PSMA ligands occurs in the salivary glands, liver, 
spleen, kidneys, and intestines, as well as neovasculature which may express PSMA (27). 
The location of sacral and celiac ganglia near areas of potential lymph node metastases 
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could lead to false positives and misdiagnosis, and in one study, 68Ga-PSMA-11 uptake was 
found in at least one ganglion in 89% of patients evaluated (34).  Other cases of false 
positives include benign diseases such as sarcoidosis and Paget’s disease, which have 
been shown to have PSMA-radiotracer uptake (34). The spatial resolution of the clinical PET 
scanner (5 mm) may lead to false negative diagnosis of lymph node metastases, and the 
lack of PSMA overexpression on neuroendocrine differentiated prostate cancer could also 
lead to misdiagnosis (34). The development of tracers targeting other antigens, as well as 
multi-modality imaging, could help address these limitations and increase specificity and 
sensitivity. 
 
1.2.11 Other targets for prostate cancer PET imaging  
GRPR  
The gastrin-releasing peptide receptor (GRPR) is overexpressed on cancers such as 
prostate cancer, and at low levels of normal prostate. However, although one study showed 
positive correlation between GRPR expression and Gleason score, conflicting results from 
another study showed an inverse correlation between GRPR and Gleason, PSA, and tumor 
size (35). Agonists such as AMBA have been radiolabeled with 68Ga for PET in preclinical 
and clinical studies, and 177Lu for RIT in several prostate cancer models. Antagonists can 
target GRPR without activation and internalization of the receptor and have been 
hypothesized to provide superior tumor-to-organ contrast; several antagonists have bene 
evaluated for PET imaging in preclinical models (35). Lastly, a dual-targeting heterodimer 
bombesin-RGD that binds both GRPR and the integrin αvβ3 was radiolabeled with 68Ga and 
evaluated in a Phase I trial. 68Ga-BBN-RGD PET detected more lesions compared to 68Ga-
BBN, although 68Ga-RDG was not compared (36). However, it is not yet clear when to best 
use 68Ga-BBN-RGD to guide therapy selection or identify disease heterogeneity (37). 
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PSCA 
Prostate Stem Cell Antigen (PSCA) is a cell-surface marker upregulated in the majority of 
prostate cancers and metastases, as well as pancreatic, bladder, and stomach cancer (38). 
Increased expression of PSCA correlates with more severe tumor stage, Gleason score, and 
progression towards androgen independence (39,40). As a cell-surface marker, PSCA is a 
promising target for prostate cancer imaging due to overexpression in primary prostate 
cancer (88-94%), bone metastases (87-100%), as well as lymph nodes and liver metastases 
(67%).  
 
Anti-PSCA pre-clinical molecular imaging has previously been used to detect PSCA-positive 
prostate (41,42) and pancreatic cancer (43). The anti-PSCA antibody fragment, A11 
minibody (A11 Mb) was radiolabeled with 124I and 89Zr and administered to mice bearing 
22Rv1-PSCA prostate adenocarcinoma s.c. xenografts (41). 124I-A11 Mb PET imaging was 
superior due to higher tumor-to-soft tissue contrast and therefore used in subsequent 
preclinical and clinical studies. 124I-A11 Mb successfully detected PSCA-positive intratibial 
xenografts with higher sensitivity and specificity than 18F-Fluoride bone scans (42). In mice 
treated with the anti-androgen MDV-3100, uptake of 124I-A11 Mb also decreased in 
correlation with PSCA downregulation (42), and therefore anti-PSCA imaging may be useful 
to monitor response to therapy. 
 
1.2.12 Near-infrared fluorescence imaging for intraoperative guidance  
Although molecular imaging methods can identify the whole-body extent of disease, 
surgeons currently rely on visual cues (color, morphology, elasticity) and experience to 
identify tumorous tissue. Difficulty visualizing positive margins, including extracapsular 
extensions and lymph node metastases, can increase the probability of incomplete resection 
and therefore tumor recurrence (44,45). Wide-resection strategies can damage surrounding 
tissues such as rectum, urinary sphincter, and erectile nerves, which can lead to urinary 
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incontinence and impotence (46). The transition to robot-assisted radical prostatectomy has 
improved oncological, continence, and potency outcomes (47), and this surgical 
advancement can be complemented with disease-specific optical imaging agents for further 
improvement in patient outcome. 
 
 
Figure 1.4: Targeted fluorescent imaging. A, Examples of targeted fluorophores. B, Near-
infrared fluorescence allows for deeper tissue penetration (mm) to visualize the targeted 
tumor. Figure adapted from (48) and reprinted with permission from Springer Nature. 
 
Near-infrared fluorescence (NIRF) image-guided surgery has emerged as a tool to visualize 
tumor margins for improved resection (49,50). NIR fluorophores (traditional window 700-900 
nm, recently extended to 1,700 nm (51)) allow for light penetration at a greater depth 
(millimeters) than fluorophores in the visible light range (micrometers) (50), which is 
accompanied by decreased background fluorescence and scattering and therefore 
increased signal-to-noise (Figure xx). Non-targeted fluorescence-guided surgery using 
indocyanine green (ICG) and methylene blue (MB) have been approved for use in clinical 
trials. ICG in particular has been used for sentinel lymph node mapping in a variety of 
cancers, hepatobiliary tumor imaging, and other solid tumors by passive accumulation (52). 
However, active targeting can improve tumor retention and therefore tumor-to-background 
contrast. NIR fluorophores used to conjugate to target-specific probes include IRDye800CW 
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(available clinical grade), ICG, and the cyanines Cy5, Cy5.5, or Cy7, which are more easily 
detected in a preclinical setting (50,53).  
 
1.2.13 Fluorescent imaging of prostate cancer 
Fluorescence imaging probes targeting antigens such as PSMA and PSCA have been 
developed for intraoperative guidance. The anti-PSMA antibody J591-ICG was used to 
successfully detect PSMA-positive tumors in vivo (22). PSMA-targeted small molecules have 
been used for fluorescent imaging in preclinical studies (54,55), and the anti-PSMA antibody 
MDX1201-A488 is currently being evaluated in a Phase I trial to guide robotic assisted 
radical prostatectomy (NCT02048150). PSCA-targeted antibody fragments have also been 
evaluated for fluorescence guided surgery of prostate cancer. In one study, Cy5-labeled anti-
PSCA antibody fragment (A2 cDb) detected tumors implanted intramuscularly to mimic 
invasive growth (56). Another anti-PSCA antibody fragment (A11 Mb) labeled with 
IRDye800CW identified primary orthotopic prostate tumors and metastatic lesions in mice 
expressing background human PSCA (57). Both probes were used for image-guided surgery 
to facilitate tumor resection, and overall survival was improved compared to groups receiving 
only white light surgery.   
 
1.2.14 Dual-modality imaging of prostate cancer 
Dual-modality probes are labeled with a radioisotope for PET or SPECT imaging in addition 
to a fluorophore for fluorescent imaging. Dual-modality probes can provide preoperative 
information on the location and extent of the disease, as well as intraoperative surgical 
guidance. Combining two labels on a single agent allows for correspondence between the 
two signals.  
 
In one study, mice with intraperitoneal prostate cancer lesions were administered 111In-anti-
PSMA antibody-IRDye800CW. By SPECT, all lesions were visualized, while only the 
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superficial lesions were identified by fluorescence, supporting the use of a dual-modality 
agent to localize tumors preoperatively to inform the intraoperative surgical plan (58). 
However, intact antibodies have a long circulation half-life which lead to long imaging time 
points post-injection. The small molecule PSMA-11 dual-labeled with 68Ga and IRCye800CW 
was used for PET/fluorescence imaging of xenografts in mice, as well as fluorescence-
guided prostatectomy in pigs (59). 68Ga-gastrin-releasing peptide receptor (GRPR) 
antagonist-IRDye 650 was used for PET/ fluorescence imaging of mice with prostate cancer 
xenografts, although the additional of IRDye 650 resulted in increased kidney and blood 
retention (60). Although small molecules can be successfully used for dual-modality imaging, 
they are also more prone to biodistribution changes due to conjugation to chelators or 
fluorophores. An antibody fragment allows for shorter imaging times compared to intact 
antibodies, and can be labeled with dye-to-protein ratios with minimal pharmacokinetic 
changes. Dual-labeled anti-PSCA A11 Mb (Chapter 3) (61) and A2 cDb (62) were 
successfully used to detect PSCA-positive lesions by immunoPET/fluorescence, and these 
proof-of-principal studies support the potential for clinical development.  
 
1.3 Therapy of prostate cancer 
1.3.1 Standard therapy for patients with local disease 
Expectant management 
Expectant management (watchful waiting and active surveillance) may be recommended for 
men with slow-growing localized prostate cancer, especially at an older age, because the 
benefit of more intensive therapies such as radiation may not outweigh the side effects. 
Watchful waiting involves monitoring the patient and only treating symptoms when they 
arise. Active surveillance typically includes DRE and PSA tests every 6 months, as well as 
biopsies as needed. Studies have shown that despite ultimately needing treatment, patients 
with low-risk disease have a better quality of life if they initially receive active surveillance 
instead of surgery or radiation (4).  
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Surgery 
Patients who have localized disease (Stage I/II) may undergo radical prostatectomy (RP) to 
remove the prostate. Robotic-assisted RP and laparoscopic RP methods allow for minimal 
invasiveness and sparing of surrounding nerves compared to standard open retropubic RP, 
although studies have also shown incidence in positive margins and functional outcomes are 
similar (4). Patients with intermediate and high-risk disease may also receive prostate lymph 
node dissection (PLND) or extended PLND. 
 
Table 1.4: Prostate cancer stages and corresponding standard treatments. Table based on 
(63) from the National Cancer Institute. 
 
Radiation Therapy 
Patients who have disease localized to the prostate and/or surrounding tissues but are not 
good candidates for radical prostatectomy may receive radiation therapy. External beam 
Stage (TNM) Standard Treatment 
I 
Watchful waiting or active surveillance 
Radical prostatectomy 
External-beam radiation therapy (EBRT) 
Interstitial implantation of radioisotopes 
II 
Watchful waiting or active surveillance 
Radical prostatectomy 
EBRT ± hormone therapy 
Interstitial implantation of radioisotopes 
III 
EBRT ± hormone therapy 
Hormone therapy ± radiation therapy 
Radical prostatectomy ± EBRT 
Watchful waiting or active surveillance 
IV 
Hormone therapy 
Bisphosphonates 
EBRT ± hormone therapy 
Palliative radiation therapy 
Palliative surgery with transurethral resection of prostate 
Watchful waiting or active surveillance 
Recurrent 
Hormone therapy 
Chemotherapy for hormone-resistant prostate cancer 
Immunotherapy 
Radiopharmaceutical therapy/alpha emitter radiation 
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radiation therapy (EBRT) involves the delivery of ionizing x-rays to the prostate and may be 
planned using MRI or CT. Hypofractionation allows for the delivery of a larger dose per 
fractionation (2.5-3.4 Gy x 19-28 fractions) and a lower overall dose (64). Stereotactic body 
radiotherapy (SBRT) is form of hypofractionation (6-10 Gy x 3-7 fractions) that relies on 
imaging to determine the 3D coordinates for more precise delivery than EBRT, although 
acute urogenital toxicity may be higher (64). In contrast to externally delivered radiation, 
brachytherapy involves the implantation of low-dose rate or high-dose rate radioactive 
sources (64). For low-dose rate brachytherapy, 50-125 seeds containing 125I (145 Gy) or 
103Pd (120 Gy) are directly implanted into the prostate. For high-dose rate brachytherapy, 
catheters delivering 192Ir (12 Gy/h) are temporarily placed in the prostate, and this therapy is 
often administered in the combination with EBRT.  
 
1.3.2 Standard therapy for patients with metastatic disease  
Androgen-targeted therapy  
Androgen deprivation therapy (ADT) is the primary first-line treatment for patients with 
metastatic prostate cancer, and the goal is to reduce the testosterone level to <20 ng/dL 
(65). ADT options include using lutenizing hormone-releasing hormone (LHRH) receptor 
(also known as gonadotropin receptor hormone, GnRH) agonists, AR antagonists (ie 
enzalutamide), and testosterone production inhibitors (ie abieraterone, blocks the enzyme 
CYP17) (Figure 1.5). Abiraterone is given in addition to prednisone and ongoing ADT. 
Enzalutamide also inhibits testosterone but through a separate mechanism of binding to AR. 
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Figure 1.5: Prostate cancer pathways and corresponding therapies. Reprinted from (66) with 
permission from Springer Nature. 
 
Radium-223 
Patients with bone metastases may be administered radium-223 dichloride (223RaCl2), which 
mimics calcium and binds to bone stroma that is newly formed. 223Ra is an alpha-emitter with 
a short tissue range of 85 µm (maximum) and causes double-stranded DNA breaks with 
limited cytotoxicity to healthy bone marrow. In a Phase III study, 223RaCl2 extended median 
survival (14.9 mo) compared to placebo (11.3 mo) with limited hematological toxicity (67), 
and it is offered as a potential first-line treatment for patients with mCRPC (68). 
 
Chemotherapy 
The standard chemotherapy for patients with mCRPC is a combination of docetaxel and 
prednisone. If patients received abiraterone or enzalutamide as first-line treatment, 
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docetaxel is the second-line of treatment (68). For men with metastases at first presentation, 
data from several clinical trials support the use of ADT and docetaxel as the new standard of 
care (68). 
 
1.3.3 Radioimmunotherapy overview 
Radioimmunotherapy (RIT) enables specific delivery of the therapeutic radionuclide to the 
site of disease, although the long biological half-life of intact antibodies may result in dose to 
normal tissue (69). Using an antibody fragment (discussed in section 1.4) may be 
advantageous in limiting dosage to normal organs, especially radiosensitive tissues such as 
bone marrow; however, the kidney absorbed dose must be considered for fragment sizes 
that are excreted via the renal route. Radionuclides for RIT emit beta, alpha, or Auger 
electrons and cause cytotoxic DNA damage by numerous mechanisms including via reactive 
oxygen species, single and double stranded breaks, and inhibition of DNA damage repair 
mechanisms (70,71).  
 
1.3.3 Radionuclides for radioimmunotherapy 
Beta-emitters 
Beta-emitting radionuclides for RIT have a low LET (0.2 keV/mm) and a relatively long range 
in tissue (one to several mm), and they can therefore damage tissue throughout the tumor, 
as well as adjacent normal tissue, due to cross-fire and radiation field effect across several 
millimeters (Figure 1.6). Common beta emitters include 131I, which is readily available and 
has long been used for thyroid cancer treatment. Both 131I and 177Lu co-emit a gamma 
photon that can be detected by SPECT imaging that can complement RIT. Conjugated 
antibodies radiolabeled with 177Lu and 90Y are catabolized to yield charged radiometal 
chelate metabolites that residualize in tumor cells for increased tumor retention. A 
disadvantage of 90Y is it emits almost exclusively beta particles and cannot be imaged by 
conventional methods; however, 90Y produces bremsstrahlung photons and Cerenkov 
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radiation which can be detected by SPECT and by optical Cerenkov luminescence imaging, 
respectively (72). 
 
Alpha-emitters 
Alpha emitters have a much shorter range (a few cell diameters) and a high LET (80-100 
keV/µm), and they can be effective for smaller lesions and metastases (Figure 1.6). Alpha 
emitters commonly used in RIT studies include 213Bi, 223Ra, the radiohalogen 211At, and the 
radiometal 225Ac (73). 225Ac decays into four alpha-emitting daughter particles, two of which 
emit an imageable gamma ray, and 225Ac-radiolabeled full length antibodies have been 
efficacious in tumor-cell killing in in vitro and in vivo preclinical studies (74,75), as well as 
clinical studies (76,77). 
 
Figure 1.6: Schematic representation of therapeutic radionuclides. Beta-emitters have a low 
linear energy transfer (LET) of 0.2 keV/mm and a path length of 1-10 mm, which may reach 
throughout the tumor. Alpha-emitters have a high LET (80-100 keV/µm) and a path length of 
50-90 µm, which corresponds to a few cell diameters. Auger-emitters have low energy but 
high LET (4-26 keV/µm) and a short path length of 2-500 nm. Intracellular deposit near the 
nucleus is necessary for therapeutic effect. Figure reprinted from (78) with permission from 
John Wiley and Sons. 
 
 
Beta-emitter
1-10 mm
Alpha-emitter
50-90 µm
Tumor
Auger-emitter
2-500 nm
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1.3.3 Radioimmunotherapy for prostate cancer 
Prostate cancer metastases typically localize to bone marrow and lymph nodes, and the 
prostate s also a nonessential organ; therefore, prostate cancer can easily be targeted for 
RIT (79). RIT targeting a variety of antigens have been evaluated in several preclinical and 
clinical studies, and anti-PSMA RIT has been developed the furthest in the clinic (Table 1.5). 
 
 
Table 1.5: Clinical and preclinical targets and targeting molecules in prostate cancer RIT. 
Table adapted from (79) and reprinted with permission from Elsevier. 
 
PSMA-targeted RIT in the clinic 
Although only two radioimmunotherapy agents have been approved by the FDA, 
ibritumomab tiuxetan (Zevalin®) and tositumomab (Bexxar®), RIT agents for prostate cancer 
are currently under clinical investigation. Several clinical trials have assessed PSMA-
targeted RIT in patients with mCRPC using 177Lu-radiolabeled J591 antibody, PSMA-617 
ligand, and PSMA-I&T ligand. In Phase II trial, a single dose of 177Lu-J591 was administered 
to patients with mCRPC and the maximum tolerated dose resulted in over 30% PSA decline 
  Target 
Constitution and Function of 
Target 
Targeting molecule References 
PSMA 
Integral type II membrane 
protein 
J591 mAb, PSMA 
I&T peptides 
(29,80,81) 
hK2 
Secretory protein (kallikrein-
related peptidase family) 
Murine 11B6 mAb, 
h11B6 
(82) 
Her2 
Receptor, transmembrane 
protein 
mAbs, 
ZHER2:V2Affibody 
(83,84) 
PSCA 
GPI-anchored cell surface 
antigen 
A11 minibody  unpublished 
VE cadherin  
CD 144, involved in forming 
intercellular junctions 
E4G10 mAb (85) 
MUC-1 
Glycoprotein upregulated in 
androgen-independent PCa 
cells 
m170 mAbs, anti-
MUC-1 scFvs 
(86,87) 
GRP-R 
Membrane protein, G-protein- 
coupled receptor 
AMBA bombesin 
(peptide) 
(88,89) 
Lewis Y 
Carbohydrate antigen 
Gangliosides 
hu3S193 mAb (90) 
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and survival benefit (21.8 mo vs 11.9 mo) (91). Although the hematological toxicity was 
reversible, another clinical trial evaluated the benefit of dose fractionation, which allowed for 
the delivery of a higher cumulative MTD and similar toxicity (92). As using an alpha-emitter 
may address toxicity issues, 225Ac-J591 is currently being evaluated in a Phase I trial in 
patients with mCRPC (NCT03276572). 
 
A systematic review concluded that 177Lu-PSMA-671 and 177Lu-PSMA I&T resulted in a 
better therapeutic effect and less hematologic toxicity than 177Lu-J591, although PSMA-PET 
imaging that allows for selection of patients was not yet available during the J591-based 
studies (93). In a German multicenter retrospective study, 177Lu-PSMA-617 beta-RIT (2-8 
GBq, 1-4 cycles) was given as a third-line therapy to mCRPC patients. 40% of patients 
responded after a single cycle (94), and 177Lu-PSMA-617 is currently being evaluated in a 
Phase III trial (NCT03511664). However, 40% of patients from the retrospective study did 
not have a PSA response (>50% PSA reduction from baseline), and therefore, 225Ac-PSMA-
617 alpha-RIT was explored as an alternative and evaluated in a small number of mCRPC 
patients (95). 100 kBq/kg repeated every 2 months resulted in a therapeutic effect with 
xerostomia as the dose-limiting toxicity. Due to the small patient sample, comparison cannot 
be made with 177Lu-PSMA-617 RIT, although surprisingly the toxicity for salivary glands was 
similar and may be due to small-molecule transporters rather than PSMA-expression. 
Clinical trials evaluating combination therapy with RIT are also underway, including 177Lu-
PSMA-617 and 177Lu-J591 (NCT03545165), and 177Lu-PSMA-617 and Pembrolizumab 
immunotherapy (NCT03658447).  
 
1.4 Antibodies and antibody fragments  
1.4.1 Antibody fragments 
The specificity of antibodies and antibody fragments renders them excellent agents for 
targeted delivery of radionuclides for molecular imaging and radioimmunotherapy of cell-
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surface targets in oncology and immunology. The intact IgG antibody (~150 kDa) is 
composed of antigen-binding (Fab) domains and a constant region (Fc) that interacts with 
cell-surface receptors, such as Fcγ receptors (FcγR) on immune effector cells (Figure 1.7A) 
and the neonatal Fc receptor (FcRn) involved in recycling. Advantages of using a 
radiolabeled intact antibody for RIT include the ability to deliver a significant dose to the 
target tumors, but this strategy may also lead to high radiation exposure to normal tissues. 
Therefore, protein engineering can be applied to optimize affinity, improve pharmacokinetics, 
enable uniform conjugation/radiolabeling, and guide excretion towards hepatic or renal 
routes, in order to match the needs of the final clinical application. 
 
Antibodies can be reformatted into a variety of fragments, including smaller monovalent 
fragments such as single domain antibodies and scaffolds (Figure 1.7B), and monospecific 
and bivalent fragments such as minibodies and diabodies (Figure 1.7C). Engineered 
antibody fragments that lack the Fc clear more quickly compared to full-length antibodies for 
high tumor-to-background images at shorter imaging times (next day for the minibody) (96). 
The antibody size contributes to the route of clearance, as fragments above the renal 
threshold (60 kDa) typically clear to the liver, and smaller fragments clear via the renal route. 
The shorter circulation time compared to intact antibodies also translates to lower blood 
absorbed dose that may be advantageous for radioimmunotherapy. Additionally, antibody 
fragments can tolerate additional modifications, including fluorophore conjugation for dual-
modality immunoPET/fluorescence imaging, without significant changes in the 
pharmacokinetics.  
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Figure 1.7: Intact antibody and engineered antibody fragments. Compared to A, intact IgG 
antibody, engineered antibody fragments range in size, specificity, avidity, and therefore 
pharmacokinetic properties. Several fragments and scaffolds for radionuclide delivery have 
been explored in preclinical and clinical studies, including B, monovalent antibody fragments 
and C, bivalent monospecific fragments. Figure from (78) and reprinted with permission from 
John Wiley and Sons. 
 
1.4.2 Anti-PSCA antibody fragments 
Anti-PSCA intact antibody, minibody, and diabody have been developed for immunoPET 
imaging of prostate cancer. Figure 1.8 illustrates how 124I-radiolabeled intact antibody and 
fragments immunoPET results in high contrast tumor-to-background images, with a much 
earlier optimal imaging time point for the fragments. The A11 minibody (A11 Mb) is a 
bivalent scFv-CH3 dimer (~80 kDa) with a human gamma 1 hinge. A11 Mb was generated by 
affinity maturation of the humanized anti-PSCA antibody fragment (hu1G8) using yeast scFv 
display (97). Compared to the parental hu1G8, A11 Mb has a serine to glycine substitution in 
the VL CDR3, and four other substitutions. The serum half-life (t1/2) of the minibody (5-6 h in 
mice) pairs well with longer-lived radionuclides, including positron-emitting iodine-124 (124I, 
t1/2 = 4.2 days) and zirconium-89 (89Zr, t1/2 = 3.3 days), both of which also have been 
successfully used in the clinic (96). Tumor uptake of 124I and 89Zr-minibodies peaks around 8 
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h post injection (p.i.), and unbound tracer is sufficiently cleared by 20 h p.i. to enable imaging 
in mice with high tumor-to-blood ratios. Therefore, both 124I and 89Zr-A11 Mb immunoPET 
were compared in prostate cancer preclinical models. Due to the successful detection of 
PSCA-positive xenografts as discussed in 1.2.3, A11 Mb was purified (98) for first-in-human 
immunoPET clinical studies (NCT02092948).  
 
Figure 1.8: Anti-PSCA immunoPET. The intact antibody and fragments with corresponding 
Peak tumor-to-blood contrast for the intact antibody is obtained at a longer time p.i. (168 h) 
compared to the minibody (21 h) and diabody (8h). Figure adapted with permission from the 
American Society of Clinical Oncology (96), and Zettlitz, K., unpublished.  
 
1.5 Conclusion 
Prostate cancer can be resected more easily with a dual-modality imaging agent that can 
preoperatively locate the disease and intraoperatively guide the surgery. As PSCA correlates 
124I Intact 
168 h
124I Minibody 
21 h
124I Diabody 
8 h
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with disease stage, grade, and metastatic potential, it is a promising target for molecular 
imaging based on the specificity of antibodies. Additionally, patients with metastatic 
castration-resistant disease who no longer respond to currently available therapies could 
benefit from alternative options. Radioimmunotherapy harness the power of antibodies and 
cytotoxic radionuclides, and immunoPET can also inform dosimetry and patient selection. 
 
In this dissertation, I evaluate the use of anti-PSCA A11 cys-minibody and A11 minibody for 
dual-modality immunoPET/fluorescence imaging and radioimmunotherapy of prostate 
cancer, respectively. In Chapter 2, I characterize the A11 cys-minibody to confirm binding 
and similar affinity to the parental A11 minibody, and I test site-specific conjugation to the 
near-infrared fluorophore Cy5.5 and characterize A11 cys-minibody-Cy5.5 in vitro. In 
Chapter 3, I evaluate 124I-A11 cys-minibody-Cy5.5 dual-imaging in two subcutaneous 
prostate cancer models and 89Zr-A11 cys-minibody-Cy5.5 in an orthotopic model. In Chapter 
4, I compare the dosimetry of 131I- and 177Lu-A11 minibody to determine which beta-emitter 
results in a better therapeutic index, and I evaluate the chosen radiolabeled A11 minibody 
for radioimmunotherapy of a PSCA-positive subcutaneous prostate cancer model.  
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2 Development of the anti-PSCA 
A11 cys-minibody 
 
 
2.1 Introduction 
2.1.1 PSCA-targeting antibodies  
Prostate stem cell antigen (PSCA) is a glycoprotein (123 amino acids) attached to the cell 
membrane by a GPI anchor. The mRNA is expressed in the basal cells of the prostate, while 
the protein is expressed in the basal, secretory, and neuroendocrine cells. In normal tissues, 
PSCA is expressed in the bladder and neuroendocrine cells of the stomach and colon as 
detected by immunohistochemistry. 
 
Hybridoma screening was used to generate murine anti-PSCA antibodies including 1G8, 
which recognizes an epitope located in the middle of PSCA (amino acids 46-85) (40). 
Humanization was achieved by grafting the complementarity-determining regions (CDRs) to 
the human Fv framework of anti-p185HER2 4D5v8 (trastuzumab). Yeast scFv display was 
used to generate affinity matured minibody variants A2, A11, and C5. A11 ranked second in 
affinity and was selected as the best tracer for immunoPET imaging (97).  
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The A11 minibody was previously developed for immunoPET imaging of prostate cancer. 
124I-A11 Mb and 89Zr-A11 Mb immunoPET were compared in preclinical models, and 124I-A11 
Mb resulted in superior tumor-to-soft tissue contrast in mice bearing 22Rv1-PSCA human 
prostate carcinoma xenografts (41). The longer positron ranges of 124I and 89Zr influence 
resolution, and therefore partial-volume correction was applied to improve ex vivo 
quantification. 124I-A11 Mb PET was also evaluated in an intratibial tumor model representing 
bone metastasis and successfully detected intratibial xenografts with higher sensitivity and 
specificity than 18F-NaF bone scans (42). Additionally, decreased tumor uptake of 124I-A11 
Mb in response to enzalutamide treatment corresponded with PSCA downregulation, and 
was detectable before the tumor volume changed. Therefore, immunoPET of PSCA may be 
explored for clinical translation to monitor response to androgen deprivation therapy. The 
success of A11 Mb as an immunoPET probe naturally led to the consideration of using the 
minibody for dual-modality immunoPET/fluorescence imaging. 
 
2.1.2 Site-specific labeling and the development of A11 cMb. 
Antibodies can be conjugated to moieties such as fluorophores or radiometal chelators 
typically by N-hydroxysuccinimide (NHS) or isothiocyanate (SCN) chemistry, which react 
with the ε–amino group of lysines on the antibody and require alkaline conditions (pH 7.2-9). 
However, residues such as lysines are distributed randomly throughout the antibody, and 
therefore conjugation location and degree of labeling cannot be controlled. In contrast, 
site-specific labeling, such as modification based on cysteine residues, glycans, peptide 
tags, and unnatural amino acids, allows for more precise control of the conjugate-to-protein 
ratio (99). Site-specific labeling is also advantageous to improve the homogeneity of the 
product, and to reduce changes in affinity by directing conjugation away from the binding 
sites. 
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In previous studies, 124I radiolabeling (randomly labels to tyrosines) did not affect PSCA-
binding of A11 Mb. Therefore, for immunoPET/fluorescence imaging, the anti-PSCA 
fragment was strategized to be dual-labeled by random radiolabeling with 124I or 89Zr 
(chelated by SCN-DFO, which randomly labels to lysines), and site-specifically conjugating 
with the fluorophore. The fluorophore can be conjugated to solvent-exposed cysteines using 
thiol-labeling strategies such as maleimide chemistry, which can occur at pH 7, favorable for 
antibodies. In the CH3 domain, a C-terminal cysteine was engineered to produce the A11 
cys-minibody (A11 cMb). The sequence of A11 cMb and structural model of the variable 
regions are shown in Figure 2.1. Biochemical characterization of the A11 cMb and A11 cMb 
conjugated with maleimide-Cy5.5 (A11 cMb-Cy5.5) are presented in this chapter. 
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Figure 2.1: A11 cys-minibody. A, Annotated A11 cMb sequence, with the complementarity 
determining regions (CDRs) determined by enhanced Chothia numbering scheme. The Igκ 
leader is cleaved during protein secretion. The sections underlined in pink and red 
respectively correspond to the CDRs in the light chain and heavy chain. B, 3D model of the 
A11 cMb variable domains VL (light) and VH (heavy) as computed by SWISS-MODEL 
homology modeling software and visualized in Pymol. 
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2.2 Methods 
2.2.1 Cloning 
A11 cMb was engineered by Dr. Richard Tavaré using site-directed mutagenesis to add a 
cysteine residue (GGGGSGGC) to the C-terminus of the parental anti-PSCA A11 Mb (41). 
Mr. Felix Bergara subcloned A11 Mb from the vector pEE12 to the vector pSecTag2 A 
(Thermo Fisher).  
 
2.2.2 Protein production and purification 
Dr. Richard Tavaré used the vector pSecTag2 A to transfect human embryonic kidney cells 
(HEK 293-F, Life Technologies) by lipofection (Lipofectamine 2000, Thermo Fisher). Zeocin 
selection was used to generate a stable cell line, and cells were grown in triple flasks and 
cultured in serum-free media (Opti-MEM, Thermo Fisher). The collected supernatant (2-4 L) 
was concentrated using tangential flow filtration to 50 mL and loaded onto a HiTrap Protein L 
column (GE Healthcare) in PBS using an ÄKTA Purifier (GE Healthcare). A11 cMb protein 
was eluted using an increasing amount of elution buffer (0.1 M glycine, pH 2.0) using in a 
three-step process (30%, 60%, 100%) for the first three purifications, and using a two-step 
process (80%, 100%) in later purifications. The protein was neutralized in 1 M Tris, pH 8.2, 
and dialyzed three times in a dialysis cassette (Slide-a-Lyzer, Thermo Fisher) added to 4 L 
of PBS. The dialyzed protein was concentrated (Vivaspin 2, Sartorius) to ~1-2 mg/mL, filter-
sterilized, and stored at 4ºC.  
 
2.2.3 Protein characterization 
The purity, assembly, and size of A11 cMb was tested using SDS-PAGE (Coomassie stain) 
analysis and size exclusion chromatography (SEC). For SEC, a Superdex 200 10/30 GL 
column (GE Healthcare) was used with an ÄKTA purifier (GE Healthcare) with PBS as the 
mobile phase (0.5 mL/min). Absorbance at 280 nm (protein) was recorded. The following 
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protein standards were used: beta-amylase (200 kDa), bovine serum albumin (66 kDa), and 
carbonic anhydrase (29 kDa) (Sigma). Dynamic light scattering of A11 cMb (7.5 nm) was 
accomplished on a particle size analyzer (Brookhaven ZetaPALS) and compared with 
Bovine Serum Albumin (66 kDa, 6.2 nm) and another minibody fragment (GA101Mb ~80 
kDa, 7.2 nm), and the size distribution by number was analyzed on BIC Particle Sizing 
Software.  
 
2.2.4 Conjugation 
A11 cMb was site-specifically labeled with maleimide-Cy5.5 (mal-Cy5.5) by selective 
reduction of and conjugation to C-terminal cysteines (Figure 2.2). In a typical reaction, 200 
µg of protein at 1 mg/mL in phosphate-buffered saline (PBS) was reduced using a 2-fold 
molar excess of tris(2-carboxyethyl)phosphine (TCEP, Pierce) for 30 min at room 
temperature. Equimolar mal-Cy5.5 (Amersham, GE Healthcare) was added to the reduced 
A11 cMb for 2 h at room temperature. Excess mal-Cy5.5 was removed using a Micro Bio-
Spin™ Size Exclusion Columns (Bio-Rad) pre-equilibrated with PBS. Dye-to-protein ratio 
(D:P) was determined by measuring the protein (280 nm, A11 cMb extinction coefficient = 
133950 Mol-1 cm-1) and Cy5.5 absorbance (675 nm, preset by manufacturer) with a 
spectrophotometer (NanoDrop 2000) and using the formula ratio=dye (µM)/protein (µM).  
 
Figure 2.2: Schematic of A11 cMb site-specific conjugation. To generate A11 cMb-Cy5.5, C-
terminal cysteines are reduced and react with thiol-directed maleimide-Cy5.5.  
 
A11 cMb
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2.2.5 A11 cMb-Cy5.5 characterization 
Successful conjugation was confirmed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and size exclusion chromatography (SEC).  
SEC was performed similar to analysis of A11 cMb (2.2.3). Absorbance at 280 nm (protein) 
and 675 nm (Cy5.5) was recorded. 
 
Mass spectrometry of A11 cMb and A11 cMb-Cy5.5 was completed at City of Hope. 
Samples were reduced and alkylated using iodoacetamide, then digested using trypsin and 
GluC. Unmodified cysteines in the peptide digests are carbamidomethylated, a post-
translational modification with a mass shift of +57. Modified cysteines, such as the C-
terminal cysteine in A11 cMb Cy5.5, show a mass shift of +1038 from the mal-Cy5.5 
conjugation. 
 
2.2.6 Affinity of A11 cMb and conjugated derivatives 
The 22Rv1-PSCA cell line was previously generated by transducing 22Rv1 human prostate 
cell line (ATCC CRL-2505) with retrovirus to express PSCA (100). The PC3 human prostate 
cell line (ATCC CRL-1435) was previously transfected to express PSCA (100) and FLuc to 
produce the PC3-PSCA-FLuc cell line. These cells were used to determine the apparent 
affinity of A11 cMb by flow cytometry. A11 cMb and A11 cMb-Cy5.5 were each incubated 
with 100,000 cells at concentrations varying from 0-1 µM (2 hours on ice, triplicate). Samples 
were washed three times with PBS + 1% FBS + 0.02% sodium azide. Goat anti-human IgG-
Dylight 649 (Jackson ImmunoResearch Laboratory, Inc.) was the secondary antibody used 
to detect bound A11 cMb as previously described (41). Samples were run on the BD-
LSRFortessa X-20 analyzer and the results were analyzed using FlowJo (v9.3.2) to 
determine mean fluorescence intensity of the cells. GraphPad Prism 7.0a was used to fit the 
data using the one site saturation binding model. 
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2.3 Results 
2.3.1 Production/purification 
Due to low protein yield from a pooled transfection (0.4 mg/L), single colony selection was 
used to obtain a higher producing stable cell line (0.6-0.7 mg/L). (make comment on failed 
attempts to get better producer and could be helpful to re-engineer sequence?) 
2.3.2 Biochemical characterization of A11 cMb 
Purity and correct assembly of the A11 cMb (scFv-CH3 dimer) was confirmed by SDS-PAGE 
analysis and SEC. A11 cMb migrated as a single band approximately at the molecular 
weight calculated from the sequence (80.02 kDa) (Figure 2.3A). The size of the A11 cMb 
was estimated to be 70 kDa from interpolation of the SEC elution profile with known SEC 
standards (Figure 2.3B). A mean hydrodynamic diameter of 7.5 nm for A11 cMb was 
determined by dynamic light scattering (Figure 2.3C). 
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Figure 2.3: Biochemical characterization of A11 cMb. A, Purity and correctly assembly of 
A11 cMb was confirmed by SDS-PAGE. Under non-reducing conditions (NR), A11 cMb 
migrated as a covalently bound scFv-CH3 homodimer approximately at 80 kDa as expected 
for a minibody. Under reducing conditions (R), A11 cMb migrated as a scFv-CH3 monomer. 
C, The size of A11 cMb was estimated to be 70 kDa from interpolation with the SEC 
standards of 200, 66, and 29 kDa. D, The mean hydrodynamic diameter of A11 cMb was 
estimated to be 7.5 nm as measured by dynamic light scattering, with a size distribution 
ranging from 6.1-11.6 nanometers (nm). 
 
2.3.3 Biochemical characterization of A11 cMb conjugated derivatives 
Purity and correct assembly of the A11 cMb site-specifically conjugated with the near-
infrared dye mal-Cy5.5 was confirmed by SDS-PAGE analysis and size exclusion 
chromatography (SEC) (Figure 2.4). A11 cMb-Cy5.5 migrated as a single band 
approximately at the molecular weight as unconjugated A11 cMb (80 kDa) (Figure 2.4A). 
A11 cMb-Cy5.5 and dual-labeled DFO-A11 cMb-Cy5.5 (Section 3.2.6) eluted as single 
peaks (27.07 min and 27.01 min, respectively) similar to the unconjugated A11 cMb, 
confirming that dimeric minibody conformation was not impaired (Figure 2.4B). Similar 
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elution profiles of the absorbance at 280 nm (protein) and 675 nm (Cy5.5) demonstrated the 
fluorophore was associated with the protein (Figure 2.4B). Mass spectrometry confirmed 
modification with Cy5.5 was specific to the C-terminal cysteine leaving the hinge unmodified 
(Figure 2.4C).  
 
Figure 2.4: Biochemical characterization of A11 cMb-Cy5.5. A, The Cy5.5 label visualized by 
unstained SDS-PAGE corresponds to the A11 cMb-Cy5.5 protein band visualized by 
Coomassie. B, Size exclusion chromatography (SEC) elution profiles show A11 cMb, A11 
cMb-Cy5.5, and DFO-A11 cMb-Cy5.5 elute in a single peak (27.00 min, 27.07 min, and 
27.01 min, respectively), demonstrating the conjugations did not disrupt the minibody dimeric 
conformation (protein at 280 nm, Cy5.5 at 675 nm). Absorption at 675 nm (Cy5.5) is higher 
for the conjugated A11 cMb samples. C, Mass spectrometry of peptides resulting from 
trypsin and GluC digests covered all cysteine residues. Only the peptide (boxed in red) with 
the C-terminal cysteine showed a mass shift of +1038, which was observed in the A11 cMb-
Cy5.5 sample and not the A11 cMb sample. 
 
2.3.4 Affinity studies 
Flow cytometry analysis showed strong binding of A11 cMb-Cy5.5 to PSCA-expressing cells 
(22Rv1-PSCA). The selectivity for PSCA was confirmed using PSCA-negative cells (22Rv1) 
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(Figure 2.5A). The apparent affinity (KD value) calculated from saturation binding curves for 
A11 cMb-Cy5.5 (16.7 ± 3.4 nM, n=4, Figure 2.5B) was comparable to that of the parental 
A11 Mb (13.7 ± 1.4 nM, (42)). This was also similar to the apparent affinities of A11 cMb-
Cy5.5 (22.7 ± 2.7 nM, n=7) and dual-labeled DFO-A11 cMb-Cy5.5 (26.8 ± 2.3 nM, n=3) to 
PC3-PSCA cells (data not shown) (P>0.05 for all). 
 
Figure 2.5: Binding and affinity of A11 cMb-Cy5.5. A, Flow cytometry analysis shows A11 
cMb-Cy5.5 binding specifically to 22Rv1-PSCA cells. No binding to control 22Rv1 cells was 
detected. B, Saturation binding study of A11 cMb-Cy5.5 (22Rv1-PSCA and 22Rv1 cells) was 
used to calculate half-maximal binding KD using a one-site specific binding model (n=3, 
GraphPad). 
 
2.4 Discussion 
A11 cMb was successfully produced, and biochemical characterization (SDS-PAGE, SEC) 
was similar to parental A11 Mb as expected. The theoretical properties of both A11 Mb and 
A11 cMb are shown in Table 2.1.  
 
Studies have shown that binding affinity can be affected by conjugation of large hydrophobic 
moieties, such as near-infrared fluorophores (101). Therefore, the site-specific Cy5.5 
modification was directed to engineered C-terminal cysteine away from the antigen binding 
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sites. Cy5.5 conjugation conditions were established (mild TCEP reduction) that resulted in 
A11 cMb-Cy5.5 with a dye-to-protein ratio of 0.6-0.8, and mass spectrometry confirmed the 
fluorophore was conjugated only to the C-terminal cysteine. A11 cMb-Cy5.5 retained low 
nanomolar affinity binding to PSCA-positive cells and was used in following dual-modality 
imaging studies (Chapter 3). 
 
 
 
Molecular 
weight 
Isoelectric 
point 
Extinction 
coefficient 
Affinity to 
22Rv1-PSCA 
A11 Mb 78.53 kDa 7.21 133825 Mol-1 cm-1  13.7 ±  1.4 nM 
A11 cMb 80.02 7.11 133950 Mol-1 cm-1 16.7 ± 3.4 nM 
 
Table 2.1: Theoretical and affinity properties of A11 Mb and A11 cMb. Molecular weight, 
isoelectric point, and extinction coefficients were calculated using the ExPASy Bioinformatics 
Resource Portal. 
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3 Dual-modality imaging 
3.1 Introduction 
3.1.1 Dual-imaging 
A dual-labeled molecule ensures that the radioactive and optical signals are carried on the 
same molecule, and therefore targeting and imaging will be consistent. Dual-labeled 
antibodies and peptides for SPECT/fluorescence and PET/fluorescence have been 
evaluated in several preclinical models (102) including PSMA-positive prostate cancer 
(58,103-105). Indium-111-DOTA-girentuximab-IRDye800CW was successfully used in a 
recent clinical trial for preoperative and intraoperative guidance in renal cell carcinoma 
patients (106). We propose that engineered antibody fragments are highly suited for dual-
labeling without perturbation of their kinetics and targeting, and offer next-day high contrast 
immunoPET and fluorescence images. A recent study successfully used a dual-labeled 
antibody fragment, 124I-A2 cDb-IRDye800CW, for same-day immunoPET/fluorescence to 
detect PSCA-positive patient-derived pancreatic cancer xenografts (62). Therefore, dual 
immunoPET/fluorescence imaging with an anti-PSCA antibody fragment could be used to 
detect PSCA-positive prostate cancer. This chapter is adapted from text and figures 
originally published in (61). 
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3.1.2 ImmunoPET radionuclides 
For immunoPET using larger antibody fragments such as the minibody, longer-lived 
radionuclides such as 89Zr and 124I can pair well for optimal imaging contrast 24-48 hours 
post-injection. 89Zr-chelate metabolites cannot diffuse through cell membranes, which results 
in increased uptake at target tumor tissues but also in normal tissues. In contrast, probes 
radioiodinated via standard methods metabolize to free radioiodide or iodotyrosine, which 
readily efflux from the cell and are rapidly cleared from systemic circulation, resulting in 
reduced background although overall activity at tumor tissues may decrease over time. 
 
3.1.3 Fluorophores 
Near-infrared fluorophores allow for greater depth penetration compared to fluorophores in 
the visible light range. While IRDye800CW has been approved for use in the clinic, cyanines 
such as Cy5.5 are more easily detected in a preclinical setting. Therefore, Cy5.5 was used in 
the following dual-modality studies. 
 
3.1.4 Evaluation of dual-labeled A11 cMb 
The cysteine-modified humanized anti-PSCA A11 Mb (A11 cMb) was developed and dually 
labeled for successive immunoPET/fluorescence imaging (Figure 3.1). The efficacy was 
demonstrated in two subcutaneous models and one orthotopic prostate cancer model, and 
dual-labeled A11 cMb was successfully used to detect PSCA-positive tumors with both 
imaging modalities.  
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Figure 3.1: Concept of dual-modality imaging with A11 cMb. Dual-labeled A11 cMb showed 
specific targeting to PSCA-positive prostate tumors, thereby enabling preoperative 
immunoPET and successive intraoperative fluorescence image guidance. Figure originally 
from (61). 
 
3.2 Methods 
3.2.1 Cell lines and xenografts 
Male nu/nu mice (Foxn1nu, Jackson Laboratories) were used for all tumor models. The 
22Rv1 human prostate cell line (ATCC) was previously transduced with retrovirus to express 
PSCA (22Rv1-PSCA) (100). To establish tumors, 0.5-1x106 22Rv1 or 22Rv1-PSCA cells in 
1:1 PBS:Matrigel (BD Bioscience) were implanted s.c. in the shoulder of 8- to 10-week-old 
male nu/nu mice (25-30 g) and allowed to grow for 3-4 weeks. Mice were fed alfalfa-free 
food to reduce autofluorescence in the stomach contents, although they still emitted 
fluorescent signal. 
 
22Rv1-PSCA was transfected with Firefly Luciferase (FLuc)-IRES-GFP (22Rv1-PSCA-FLuc) 
as previously described (42). For the orthotopic intraprostatic model, 5x103 22Rv1-PSCA-
FLuc cells in 5 µl Hank’s Buffered Saline Solution (Sigma) were surgically implanted into the 
anterior lobe of the prostate (107). Mice were monitored weekly by bioluminescence, and 
tumors were allowed to grow for 6 weeks post-implantation. 
The PC3 human prostate cell line (ATCC) was previously transfected to express PSCA (100) 
and FLuc to produce the PC3-PSCA-FLuc cell line. 0.5-1x106 PC3 and PC3-PSCA-FLuc 
Cy5.5
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Preoperative 
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Intraoperative 
near-infrared 
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cells in 1:1 PBS:Matrigel were implanted in the shoulder of male nu/nu mice and allowed to 
grow for 3-4 weeks.  
 
3.2.2 Quantitation of PSCA cell surface expression 
22Rv1-PSCA antigen binding capacity (ABC) (Quantum Simply Cellular, Bangs 
Laboratories), representative of the PSCA cell surface density, was quantified by flow 
cytometry as 2.1x106 ± 2.5x105 (n=2) similar to previous published results (41). PC3-PSCA-
FLuc was quantified to have an ABC of 5.2 x105 ± 2.6x105 (n=3). 
 
3.2.3 Dual-labeling of A11 cMb 
The schematic of dual-labeling is shown in Figure 3.2. A11 cMb-Cy5.5 conjugation was 
completed as described in chapter 2. Preliminary imaging studies (show these images?) with 
a higher D:P of 2:1 showed altered pharmacokinetics and biodistribution with higher uptake 
in the liver. Therefore, the optimized dye-to-protein (D:P) molar ratio of 0.6-0.8:1 was used to 
minimize impacting the biodistribution. 
 
124I iodination of A11 cMb and A11 cMb-Cy5.5 
124I-A11 cMb, and 124I-A11 cMb-Cy5.5 were prepared using pre-coated Iodogen tubes 
according to the manufacturer’s instructions (Pierce). In a typical reaction, 100 µg of 1 mg/ml 
A11 cMb or A11 cMb-Cy5.5 was incubated with 0.5 mCi (18.5 MBq) Na-124I (3D Imaging 
LLC) in 0.1 M Tris, pH 8.0 for 10 min at room temperature.  
 
SCN-DFO and 89Zr radiolabeling of A11 cMb 
A11 cMb was conjugated with the metal chelator p-isothiocyanatobenzyl-deferoxamine (p-
SCN-Bn-DFO, B-705, Macrocyclics) for 89Zr-radiolabeling (108). In a typical reaction, 3-fold 
molar excess p-SCN-Bn-DFO was added to A11 cMb or A11 cMb-Cy5.5, and the reaction 
was immediately adjusted to pH 9 using 0.1 M sodium bicarbonate (1/10 volume). The 
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reaction was allowed to proceed for 30 min at 37ºC, and excess SCN-DFO was removed by 
size exclusion spin column. 
 
89Zr-oxalate (3D Imaging LLC) in 1 M oxalic acid was buffered in 2 M Na2CO3 (0.4x volume 
of 89Zr) and 1 M HEPES pH 7.2-7.5 (2.5x volume of 89Zr) (108). In a typical reaction, 89Zr-
A11 cMb-Cy5.5 was prepared by incubating 100 µg of 1 mg/ml DFO-A11 cMb-Cy5.5 with 
0.5 mCi (18.5 MBq) 89Zr at pH 7 for 1 h at room temperature.  
 
Figure 3.2: Schematic of the dual-labeled A11 cMb. Site-specific labeling to the A11 cMb C-
terminal cysteines (reduced with TCEP) by maleimide-thiol chemistry. For radiolabeling, 124I 
and SCN-DFO (chelates 89Zr) are randomly labeled to surface exposed tyrosine or lysine 
residues, respectively. Figure originally from (61). 
 
3.2.4 Labeling efficiency, purification, immunoreactivity 
Radiolabeled proteins were purified by size exclusion spin columns pre-equilibrated with 1% 
fetal bovine serum (FBS)/PBS. Radiolabeling efficiency and radiochemical purity were 
assessed by Instant Thin Layer Chromatography (ITLC strips for radiolabeled antibodies, 
Biodex Medical System) with 20 mM citrate pH 5.0 as the solvent for 89Zr-labeled proteins 
and saline (0.9% sodium chloride) as the solvent for radioiodinated proteins. The strips were 
analyzed by gamma counting (Wizard 3” 1480 Automatic Gamma Counter, Perkin-Elmer). 
The immunoreactive fraction was determined by the Lindmo method (1x106 to 50x106 cells) 
(109). Radiolabeled A11 cMb (0.9-1.8 ng) was incubated with excess antigen using 22Rv1-
PSCA (50x106 cells) or PC3-PSCA (50x106 cells) in 0.5 mL 1% FBS/PBS in triplicate for 1 h 
at room temperature. 22Rv1 or PC3 cells were used as a negative control. Cells were 
Random labeling 
124I or 89Zr (-DFO-SCN)
Site-specific labeling
mal-Cy5.5 or mal-DFO
S-S Cy5.5 Cy5.5
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centrifuged and washed twice in 1% FBS/PBS, and the cell pellet and supernatant were 
assessed by gamma counter.  
 
3.2.5 Dual immunoPET/fluorescence imaging 
Mice were administered Lugol’s potassium iodide solution (Sigma-Aldrich) and potassium 
perchlorate (Sigma-Aldrich) to block nonspecific thyroid and stomach uptake, respectively 
(110,111). 124I-A11 cMb (n=3, bilateral 22Rv1 and 22Rv1-PSCA s.c.), 124I-A11 cMb-Cy5.5 
(n=3, bilateral 22Rv1 and 22Rv1-PSCA s.c.; n=5, bilateral PC3 and PC3-PSCA s.c.), or 89Zr 
A11 cMb-Cy5.5 (n=5, orthotopic 22R1-PSCA) (20-90 µCi, 0.74-3.33 MBq, 10-20 µg) in 0.1 
mL saline was injected via tail vein. Immediately after injection or at 22 h p.i., mice were 
anesthetized with 1.5% isoflurane and 10-min static scans were acquired using an Inveon 
microPET scanner (Siemens), followed by 1-min microCT scans (CrumpCAT (112)).  
Following microPET/CT scans, post-mortem NIRF imaging was completed with the skin 
removed in the IVIS Lumina II (Perkin Elmer) using the following settings: emission = Cy5.5, 
excitation = 675 nm, 1 s exposure. The tumors and organs were excised and imaged ex vivo 
to compare relative fluorescence signals without obstruction by other organs. 
 
3.2.6 Biodistribution 
Following the final imaging time point, blood and organs were collected, weighed, and 
gamma-counted for ex vivo biodistribution. Uptake was calculated as % injected dose per 
gram of tissue (%ID/g) based on a standard containing 1% of the ID. 
 
3.2.7 Image analysis 
MicroPET images were reconstructed by ordered subset expectation maximization-
maximum a posteriori (OSEM-MAP, Inveon Acquisition Workplace). Images were analyzed 
and displayed using AMIDE (113). MicroPET/CT overlays are displayed as maximum 
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intensity projections (MIP) of the whole-body or 0.2 mm transverse slices. Fluorescence 
images were analyzed using the Living Image software (Perkin Elmer). Biodistribution 
graphs are depicted as box-and-whiskers (min to max), using GraphPad Prism (version 7.0a 
for Mac OS X, GraphPad Software). Statistical analysis was performed using multiple 
Student t tests, the significance threshold was set at 0.05, and p-values were corrected 
using the Holm-Šídák method. All values in the tables are reported as mean ± SD. 
 
3.2.8 Histology and immunohistochemistry 
Freshly isolated tumors and organs of interest were fixed in 10% formalin/PBS. Samples 
were embedded in paraffin (UCLA Translational Pathology Core Laboratory) and sectioned 
into 4 µm sections, which were then stained with H&E or anti-PSCA antibody (ab56338, 
Abcam). 
 
3.3 Results 
3.3.1 Radiolabeling 
124I-A11 cMb and 124I-A11 cMb-Cy5.5 had specific activities of 1.0-3.9 µCi/µg (37-144 
KBq/µg) and 0.6-5.9 µCi/µg (22-219 KBq/µg), respectively, and both probes retained high 
immunoreactivity to PSCA-positive cells (>70%) (Table 3.1). 
89Zr-A11 cMb-Cy5.5 had specific activities of (insert range, average 5.8 µCi/µg) and retained 
high immunoreactivity to PSCA-positive cells (>70%) (Table 3.1).  
 
 124I-A11 cMb 124I-A11 cMb-Cy5.5 89Zr-A11 cMb-Cy5.5 
Radiolabeling 
Efficiency 
81 ± 21% 
n=3 
69 ± 23% 
n=6 
99 ± 1% 
n=3 
Radiochemical 
Purity 
99.1 ± 0.6% 
n=3 
99.1 ± 0.90% 
n=6 
99.7 ± 0.1% 
n=2 
Specific Activity 2.5 ± 1.5 µCi/µg 
n=3 
3.3 ± 2.1 µCi/µg 
n=6 
5.8 ± 0.7 µCi/µg 
n=3 
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Immunoreactive 
fraction (r) for 
22Rv1-PSCA 
>0.76 
n=3 
>0.76 
n=4 
0.77 
n=1 
Immunoreactive 
fraction (r) for  
PC3-PSCA 
n/a 0.82 
n=1 
0.80 
n=1 
Values are reported as mean ± standard deviation (SD). 
Table 3.1: Radiolabeling and immunoreactivity for 124I-A11 cMb, 124I-A11 cMb-Cy5.5, and 
89Zr-A11 cMb-Cy5.5. Table originally from (61). 
 
3.3.2 ImmunoPET/fluorescence imaging in PSCA-high s.c. model 
For the 22Rv1-PSCA s.c. model, 20 µg of 124I-A11 cMb or 124I-A11 cMb-Cy5.5 with a final 
D:P of 0.7:1 was injected into nude mice. High contrast immunoPET images acquired 22 h 
p.i. showed specific uptake of 124I-A11 cMb or 124I-A11 cMb-Cy5.5 in the 22Rv1-PSCA 
tumors compared to minimal uptake in the antigen-negative 22Rv1 tumors, blood, and 
background tissues (Figure 3.3A, B).  
Chapter 3: Dual-modality imaging 
    51 
 
Figure 3.3: 
124
I-A11 cMb-Cy5.5 immunoPET/fluorescence of 22Rv1-PSCA s.c tumor-bearing 
mice. A, 
124
I-A11 cMb and B 
124
I-A11 cMb-Cy5.5 PET/CT scans show antigen specific 
uptake in 22Rv1-PSCA tumors (+, left shoulder) and minimal nonspecific uptake in 22Rv1 (-, 
right shoulder) tumors at 22 h post-injection (nude mice, n=3 per group). Images are 
represented as whole body maximum intensity projections (MIPs). C, Ex vivo biodistribution 
(22 hours p.i.) confirms high uptake in 22Rv1-PSCA tumors and low activity in all other 
tissues. The addition of Cy5.5 at a low dye-to-protein ratio did not alter biodistribution. D, E, 
Post-mortem Cy5.5 fluorescent images show specific signal in PSCA-positive tumors. The 
signal from the stomach (St) is due to autofluorescence. Scale units R.E.= Radiance 
Efficiency. Figure originally from (61). 
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 124I-A11 cMb 124I-A11 cMb-Cy5.5 
%ID/g ± SD %ID/g ± SD 
22Rv1-PSCA 12 ± 4.2 12 ± 1.3 
22Rv1 1.7 ± 1.0 1.2 ± 0.6 
Blood 3.3 ± 0.1 1.9 ± 0.5 
Heart 1.2 ± 0.1 0.7 ± 0.3 
Lung 1.7 ± 0.1 1.2 ± 0.1 
Liver 0.6 ± 0.01 0.9 ± 0.1 
Kidney 1.1 ± 0.04 1.0 ± 0.1 
Spleen 0.7 ± 0.1 0.5 ± 0.1 
Stomach 2.1 ± 0.3 1.3 ± 0.04 
Intestine 0.4 ± 0.02 0.2 ± 0.1 
Muscle 0.2 ± 0.01 0.1 ± 0.01 
Pos:Neg Tumor 8.1 ± 2.8 13 ± 7.7 
Pos Tum:Blood 3.7 ± 1.2 6.6 ± 1.9 
Neg Tum:Blood 0.5 ± 0.3 0.6 ± 0.2 
Pos Tum:Muscle 54 ± 20 125 ± 39 
 n=3 n=3 
%ID/g: % injected dose per gram; Tum = Tumor 
Values are reported as mean ± SD. P=n.s. for all tissues 
 
Table 3.2: Ex vivo biodistribution of 124I-A11 cMb and 124I-A11 cMb-Cy5.5 in 22Rv1-PSCA 
tumor-bearing mice. Table originally from (61). 
 
Specific uptake in the PSCA-positive tumors was confirmed by ex vivo biodistribution at 22 h 
p.i., with similar values for both 124I-A11 cMb-Cy5.5 (12 ± 1.3 %ID/g) and 124I-A11 cMb (12 ± 
4.2 %ID/g, P>0.05) (Figure 3.3C, Table 3.2). Antigen specific uptake in 22Rv1-PSCA tumors 
was significantly higher than nonspecific uptake in 22Rv1 tumors, resulting in positive-to-
negative tumor ratios of 13:1 and 8:1, for 124I-A11 cMb-Cy5.5 and 124I-A11 cMb, respectively 
(Table 2). Importantly, no significant difference in uptake, clearance, and biodistribution 
between the single (124I-A11 cMb) and the dual-modality (124I-A11 cMb-Cy5.5) tracer was 
observed (Figure 3.3C, , Table 3.2). 
 
Post-mortem fluorescent imaging was completed with the skin removed in order to mimic an 
intraoperative setting. In mice injected with 124I-A11 cMb-Cy5.5, strong fluorescent signal 
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was detected in the 22Rv1-PSCA tumors with minimal background signal in 22Rv1 tumors 
and surrounding muscle (Figure 3.3D). Ex vivo optical imaging of the resected tumors 
allowed comparison of relative fluorescence signals without obstruction by other organs. 
Consistent with the in situ results, high fluorescent signal was seen in the 22Rv1-PSCA 
tumors compared to 22Rv1 tumors (Figure 3.3E). 
 
3.3.3 ImmunoPET/fluorescence imaging in PSCA-moderate s.c. model 
A subcutaneous PC3-PSCA tumor model was used to test the feasibility of imaging 
moderate levels of PSCA (5.2 ± 2.6x105 antigens/cell). MicroPET/CT of nude mice (n=5) 
bearing PC3-PSCA and control PC3 tumors showed high uptake of 124I-A11 cMb-Cy5.5 in 
positive tumors at 22 h p.i. Nonspecific uptake in the stomach and thyroid is visible in images 
set at a scale of 0.2-2 %ID/g (Figure 3.4A), as these organs scavenge free iodine and were 
likely incompletely blocked. The ex vivo biodistribution confirms the imaging results with 
significantly higher uptake in PC3-PSCA tumors (2.9 ± 0.6 %ID/g) compared to PC3 tumors 
(0.7 ± 0.4 %ID/g) (P<0.01), resulting in a positive-to-negative tumor ratio of 5.6:1, and PC3-
PSCA tumor-to-muscle ratio of 54:1 (Figure 3.4B, Table 3.3).  
 
Ex vivo optical imaging allowed comparison between the PC3-PSCA tumors, which were 
detected by Cy5.5 fluorescence, and PC3 control tumors, which had little to no fluorescence 
signal (Figure 3.4C). Ex vivo analysis showed expected autofluorescence in (stomach, 
intestines) and additional signal in liver, kidneys, and bladder due to tracer clearance ( 
Figure 3.5).  
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Figure 3.4: 
124
I-A11 cMb-Cy5.5 immunoPET/fluorescence of PC3-PSCA s.c tumor-bearing 
mice. A, 
124
I-A11 cMb-Cy5.5 PET/CT at 22 h p.i. (n=5) show specific uptake in subcutaneous 
PC3-PSCA (+) tumors and no nonspecific uptake in PC3 tumors (-). Low uptake is seen in 
thyroid (Th) and stomach (St) at this scale due to incomplete blocking, and in bladder (Bl) 
due to clearance. Images are represented as whole body MIPs. B, Ex vivo biodistribution (22 
h p.i.) confirms higher %ID/g uptake in PC3-PSCA tumors than PC3 tumors. C, Ex vivo 
fluorescence (Cy5.5) imaging revealed strong fluorescent signal in PC3-PSCA tumors and 
excellent contrast to PC3 control tumors. R.E.= Radiance Efficiency. Figure originally from 
(61). 
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89Zr-A11 cMb-Cy5.5 
%ID/g ± SD 
Prostate Tumor 3.1 ± 0.5 
Blood 0.9 ± 0.1 
Heart 2.6 ± 0.7 
Lung 2.4 ± 1.6 
Liver 18 ± 2.7 
Kidney 12 ± 1.2 
Spleen 5.1 ± 2.1 
Stomach 1.1 ± 0.2 
Intestine 2.6 ± 0.3 
Bone 4.4 ± 2.3 
Muscle 0.4 ± 0.1 
Testes 2.9 ± 1.4 
Pros Tum:Blood 3.4 ± 0.2 
Pros Tum:Muscle 7.7 ± 1.0 
 
n=4, except blood n=3 
Table 3.3: Ex vivo biodistribution of 124I-A11 cMb-Cy5.5 in PC3-PSCA tumor-bearing mice. 
Table originally from (61). 
 
Figure 3.5: Ex vivo biodistribution of 124I-A11 cMb-Cy5.5 fluorescence signal compared with 
autofluorescence. A,. Fluorescent signal is specific to the PC3-PSCA tumors, and signal is 
also present in the organs of clearance (liver, kidney, and bladder). High autofluorescence is 
present in the stomach and intestines due to the food. B, A non-tumor-bearing mouse 
biodistribution confirmed autofluorescence in the stomach, intestine, and testes. R.E.= 
Radiance Efficiency. Figure originally from (61). 
 
3.3.4 ImmunoPET fluorescence imaging in intraprostatic orthotopic model 
In order to test dual-imaging at the natural site of prostate disease, an orthotopic model was 
assessed. These studies were conducted using 89Zr because signal from 124I clearance to 
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the bladder interfered with visualization of activity accumulated in the prostate (data not 
shown). Mice were intraprostatically implanted with 22Rv1-PSCA-Fluc-GFP cells, and 
tumors grew extensively with significant bioluminescent signal (n=4) or low signal (n=1), 
which was designated “limited disease” (Figure 3.6).  
 
 
Figure 3.6: Comparison of extensive and limited intraprostatic tumors. A, 22Rv1-PSCA-GFP-
Fluc intraprostatic tumors were imaged weekly by bioluminescence to determine the time 
point for PET/fluorescence imaging. A representative prostate tumor in a mouse with 
extensive disease was quantified in comparison to the bioluminescent signal from a tumor 
with limited disease, resulting in a 2 log difference of radiance signal. Rad= radiance. B, C, 
The bioluminescence signal from extensive disease correlates with the corresponding 89Zr-
A11 cMb-Cy5.5 PET and fluorescence images of the resected prostate tumor. R.E.= 
Radiance Efficiency. Figure originally from (61). 
 
89Zr-A11 cMb-Cy5.5 immunoPET at 22 h p.i. showed specific uptake in the prostate tumors 
with extensive disease compared to minimal prostate signal in the mouse with limited 
disease (Figure 3.7A). Ex vivo biodistribution at (22 h p.i.) confirmed specific uptake in the 
22Rv1-PSCA tumors (3.1 ± 0.5 %ID/g), and the tumor-to-blood ratio was quantified to be 
3:1. Due to the residualizing nature of the radiometal, activity in organs of clearance is 
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retained at high levels compared with the iodinated A11 cMb (liver: 18 ± 2.7 %ID/g, kidneys: 
12 ± 1.2 %ID/g, spleen: 5.1 ± 2.1 %ID/g) (Figure 3.7A-B, Table 4 need to add). Nonspecific 
uptake in the bone is due to accumulation of free 89Zr. Importantly, the prostate tumor was 
clearly distinguished by post-mortem fluorescence imaging compared to adjacent seminal 
vesicles and bladder, which supports the feasibility of fluorescence guidance for prostate 
cancer surgery (Figure 3.7C). PSCA-positive tumor growth in the prostate and absence of 
neoplastic tissue in the surrounding seminal vesicles was confirmed by H&E and anti-PSCA 
immunohistochemistry (IHC) (Figure 3.7D).  
 
Figure 3.7: 89Zr-A11 cMb-Cy5.5 immunoPET/fluorescence of mice bearing 22Rv1-PSCA 
intraprostatic tumors. A, 89Zr-A11 cMb-Cy5.5 PET/CT (22 h p.i.) of nude mice (n=4) with 
intraprostatic orthotopic tumors (white dotted circle), compared to a mouse (n=1) with limited 
A
C
D
Prostate tumor Sem ves
H
&
E
P
S
C
A
B
89Zr-A11 cMb-Cy5.5, 22 h p.i.: Extensive Disease Limited disease
SV
Prostate tumor
B
Testes
Bone
Muscle
4.0
0.0
R.E. x 103 
B
5.0
0.5
%
ID
/g
L
K
B
200 µm
0 5 10 15 20 25
Bone
Spleen
Kidney
Liver
Blood
22Rv1-PSCA
%ID/g
Chapter 3: Dual-modality imaging 
    58 
disease. Top: coronal whole body MIPs, bottom: 0.2 mm transverse sections, which do not 
include the bladder, black dotted circle). B, Ex vivo biodistribution (22 h p.i.) confirms higher 
%ID/g uptake in 22Rv1-PSCA prostate tumors compared to blood, and high clearance to the 
liver and kidney. C, Cy5.5 fluorescence signal is specific to the resected prostate with little to 
no signal in surrounding seminal vesicles, bladder, or background tissues (testes, bone, and 
muscle). R.E.= Radiance Efficiency. D, H&E confirms tumor growth in the prostate, which 
stained positively for PSCA while surrounding seminal vesicles were negative for PSCA. B– 
Bladder, K– Kidney, L– Liver, SV– Seminal Vesicle. Figure originally from (61). 
 
 
3.4 Discussion 
Primary prostate cancer and regional lymph node metastases can be treated by surgical 
resection. However, patients often suffer from over and under-treatment due to inaccurate 
diagnosis or inability to visualize positive margins during surgery. Dual-modality 
PET/fluorescence imaging could provide non-invasive whole-body disease detection and 
intraoperative fluorescence guidance, and therefore improve prostate cancer treatment. 
 
In this study, the anti-PSCA antibody fragment A11 cys-minibody (A11 cMb) was used to 
generate a novel dual-modality imaging probe. A11 cMb was conjugated with the near-
infrared dye Cy5.5 and radiolabeled with either 124I or 89Zr (124I-A11 cMb-Cy5.5 and 89Zr-A11 
cMb-Cy5.5). Both tracers showed specific targeting to PSCA-expressing prostate cancer in 
vivo resulting in whole body immunoPET scans visualizing the tumors and fluorescence 
imaging distinguishing PSCA-positive cancer from surrounding healthy tissue. 
 
Dual-labeled 124I-A11 cMb-Cy5.5 and 89Zr-A11 cMb-Cy5.5 retained high immunoreactivity for 
PSCA-positive cells similar to 124I-A11 cMb (Table 1), demonstrating that dual-labeling did 
not impair binding. Fluorophore conjugation can also affect the pharmacokinetics and 
biodistribution of antibodies and small ligands (50,58), typically in the form of enhanced liver 
uptake and faster blood clearance.  124I-A11 cMb-Cy5.5 with a dye-to-protein ratio (D:P) of 
0.7-0.8:1 demonstrated similar tumor uptake and minimal changes in biodistribution 
compared with 124I-A11 cMb.  
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Fluorescence-image guided surgery has been shown to improve tumor resection in 
preclinical studies and several agents have entered clinical trials (48). Furthermore, dual-
modality imaging is increasingly studied in both preclinical and clinical studies (62,102,106). 
Imaging with a dual-labeled antibody ensures similar biodistribution in both modalities and 
facilitates clinical translation by avoiding separate testing of distinct imaging tracers. While 
immunoPET provides whole-body, quantitative information with unlimited depth, it suffers 
from low resolution and time constraints due to radioactive decay. NIRF fluorophores, on the 
other hand, show low depth of penetration (114) but excellent cell-level resolution. Unlike the 
radiolabel, the fluorophore does not have a physical half-life (cellular half-life = 3.9 days 
(101)) and therefore allows longer detection of the signal for surgical guidance. 
 
PSCA is expressed in virtually all prostate cancers (83-100%) as well as in prostate cancer 
metastases to bone and lymph nodes (38,40,115,116). However, a wide range of PSCA 
expression levels, correlating with progression and prognosis, was found by quantitative 
reverse transcriptase-PCR analysis of clinical prostate metastases specimens (115). 
Because increased PSCA corresponds with increased Gleason score and clinical stage, we 
therefore evaluated the dual-modality A11 cMb in two s.c. models with different levels of 
PSCA expression: 22Rv1-PSCA (high-PSCA) and PC3-PSCA (moderate PSCA). 
Importantly, 124I-A11 cMb-Cy5.5 immunoPET/fluorescence imaging resulted in high contrast 
PET and fluorescent images in both high- and moderate PSCA-positive prostate cancer 
models. Although antigen expression does not necessarily correlate with tumor uptake, as 
other factors such as tumor vasculature can affect accessibility, the dual-modality A11 cMb 
could facilitate detection in different stages of prostate cancer. 
 
The longer-lived radionuclides 124I and 89Zr are most commonly used for labeling antibodies, 
and in this study, we compared specific tumor uptake and contrast to normal tissue of both 
124I- and 89Zr-labeled A11 cMb-Cy5.5 in preclinical prostate cancer models. 124I and 89Zr differ 
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regarding their physical properties, protein conjugation chemistry, and biological metabolism 
which can lead to significant differences in uptake and retention of the radioactive signal. 124I 
is a nonresidualizing radiolabel, and upon internalization and degradation of radioiodinated 
proteins, metabolites including iodotyrosine freely diffuse from the cell, leading to low 
background and thereby high contrast. These characteristics are advantageous when 
imaging targets retained on the cell surface, like PSCA that has previously been shown to 
internalize slowly (41). Concordantly, immunoPET studies using 124I-labeled parental A11 Mb 
(41), 124I-A11 cMb and 124I-A11 cMb-Cy5.5 achieved high-contrast images in the 
subcutaneous models (22Rv1-PSCA, PC3-PSCA). A previous study using 124I-A11 Mb to 
image intratibial xenografts supports the hypothesis that the very low background of 124I-A11 
cMb-Cy5.5 will be advantageous for targeting bone metastases (42). In contrast, free 89Zr 
accumulates in bone and may result in false positives (117). 
 
A major benefit of imaging with a residualizing radiometal (89Zr) is better signal retention, as 
89Zr-radiometabolites get trapped in the cell upon internalization, and higher spatial 
resolution due to a shorter mean positron range (1.1 mm for 89Zr vs 3.0 mm for 124I). These 
factors are crucial when imaging small structures like the prostate, hence 89Zr-A11 cMb-
Cy5.5 was used to image orthotopic prostate cancer. A further advantage compared with 124I 
is that 89Zr is not excreted through urine, assuring minimal interference from activity in the 
bladder. 
 
89Zr-A11 cMb-Cy5.5 immunoPET/fluorescence imaging of the orthotopic model 
demonstrated successful visualization and delineation of 22Rv1-PSCA tumors growing at 
the site of natural disease, which is an important finding as tumor localization and 
accessibility are known to affect tumor targeting and tracer uptake, and may account for the 
difference in tumor uptake between the orthotopic and s.c. models. These promising results 
and the fact that the dual-modality tracer is based on a humanized antibody fragment 
suggest that 89Zr- and 124I-labeled A11 cMb-Cy5.5 could be clinically translated for imaging 
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and surgical guidance in prostate cancer. The results from an ongoing Phase I trial 
evaluating 124I-parental A11 Mb for immunoPET (NCT02092948) will inform on the 
pharmacokinetics of radiolabeled minibody in patients. 
 
Future studies should include surgical studies to mimic the clinical setting (radical 
prostatectomy) and confirm a survival benefit of resecting tumors guided by real-time 
fluorescence imaging. Furthermore, more clinically relevant metastatic prostate cancer 
models should be imaged to ensure that positive pelvic lymph nodes are detectable both 
preoperatively using 89Zr-A11 cMb-Cy5.5 immunoPET and intraoperatively using 
fluorescence, as the current clinical standard using frozen section histology to confirm which 
lymph nodes to resect is time-intensive (118). 
 
Dual-modality imaging can also be applied to antibodies against other prostate cancer 
targets. For example, GRPR has been successfully targeted by 68Ga-HZ220-IRDye 650 in 
mice bearing PC3 xenografts for PET/NIRF imaging (104), as well as by 68Ga-IRDye800CW-
BBN in a first-in-human study in patients with glioblastoma (119). Antibodies and peptides 
targeting PSMA have been extensively explored for PET (120), and more recently validated 
for optical imaging (50) and dual SPECT/fluorescence imaging (58,102,103). Dual-labeled 
111In-PSMA-targeting-urea-IRDye800CW (103) and 111In-anti-PSMA antibody D2B-
IRDye800CW (58) successfully detected prostate cancer lesions in mice by SPECT/NIRF, 
and the anti-PSMA antibody MDX1201-A488 is currently being evaluated for FIGS in 
patients receiving robotic assisted laparoscopic prostatectomy (NCT02048150). However, 
PSMA is also expressed in normal tissues, such as the ganglia close to the location of 
typical lymph node metastases, which could result in false positives, and PSMA 
overexpression is not present in 10% of patients (27). Therefore, it would be useful to also 
explore PSCA as an additional target for prostate cancer diagnosis and therapy. 
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In summary, specific targeting to human PSCA-positive prostate cancer was achieved by in 
vivo administration of 124I-A11 cMb-Cy5.5 and 89Zr-A11 cMb-Cy5.5 for immunoPET and 
fluorescence imaging. Dual-modality imaging was successful in s.c. models with high and 
moderate PSCA expression, demonstrating the ability of the A11 cMb to target a range of 
antigen expression. In the intraprostatic model, fluorescence clearly distinguished the 
prostate tumor from surrounding relevant tissues. This work has translational potential for 
noninvasive preoperative whole-body imaging and additional real-time intraoperative 
guidance in PSCA-positive prostate cancer. 
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4 Radioimmunotherapy of PSCA-
positive prostate cancer 
4.1 Introduction 
Patients with metastatic castration resistant prostate cancer (mCRPC) are often treated with 
anti-androgens, but the disease eventually progresses. Current second generation androgen 
deprivation therapies such as abiraterone or enzalutamide may extend survival by 1-2 years; 
however, 20-40% of patients do not respond, and almost all responders develop escape 
mechanisms and secondary resistance (121). Therefore, new therapy options must be 
explored. Radioimmunotherapy (RIT) uses an antibody to deliver cytotoxic radionuclides with 
beta, alpha, or Auger-emissions which cause double-stranded breaks, reactive oxygen 
species, and ultimately cell death. While beta-emitters have a longer range in tissue (up to 
few mm) and can induce damage via cross-fire, alpha-emitters have a shorter range (few 
cell diameters) and are typically more effective for smaller lesions (Figure 4.1). RIT is most 
widely used to treat lymphoma and leukemia, but recently it has been explored for treating 
solid tumors such as prostate cancer (79). 
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Figure 4.1: Schematic of RIT radionuclides. Figure reprinted from (78) with permission from 
John Wiley and Sons. 
 
Several targets have been used in preclinical and clinical RIT studies for prostate cancer, 
such as prostate specific membrane antigen (PSMA) (91,122), human kallikrein-related 
peptidase 2 (82), and prostate stem cell antigen (PSCA) (123). PSMA-targeting agents 
radiolabeled with the beta-emitter 177Lu have advanced the furthest in the clinic, including the 
small molecules 177Lu-PSMA-617 and 177Lu-PSMA I&T (93), as well as 177Lu-J591 intact 
antibody. However, 177Lu-PSMA-617 treatment resulted in xerostomia due to uptake in the 
salivary glands (94). In contrast, the J591 intact antibody does not go to the salivary glands, 
and the toxicity observed in patients who received a single dose of 177Lu-J591 was instead 
myelosuppression that was reversible (91). J591 antibody could be a viable alternative, as 
well as fragments such as the minibody (89Zr-IAB2M has been tested in patients as a PET 
agent (19)). Alternative targets including PSCA should be explored, which may improve the 
number of responders and even allow for combination RIT of more than one target. Prostate 
stem cell antigen PSCA is a cell-surface target with overexpression on the majority of 
primary and metastatic prostate cancer, low expression on normal prostate, stomach, and 
bladder, and little to no expression in radiosensitive tissues (bone marrow, kidney). Upon 
Beta-emitter
1-10 mm
Alpha-emitter
50-90 µm
Tumor
Auger-emitter
2-500 nm
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binding, PSCA internalizes slowly and is not shed, and therefore it may be a promising target 
for RIT. 
 
The goal of RIT is to deliver a high radiation dose to the tumor and minimize dose to normal 
tissues (therapeutic index), especially radiosensitive organs such as the kidney and bone 
marrow. The therapeutic index depends on the size and affinity of the antibody, radionuclide 
properties, antibody-radionuclide metabolism, and target expression. Using an antibody 
fragment, such as the minibody, may be advantageous for maximizing the therapeutic index 
due to rapid serum clearance compared to intact antibody. 124I- and 89Zr-anti-PSCA A11 
minibody (A11 Mb) immunoPET was previously used to detect prostate cancer in s.c. and 
intratibial bone metastasis models, and 124I-A11 Mb was used to monitor response to anti-
androgen therapy (41,42). Therefore, we hypothesize that the A11 Mb could be radiolabeled 
with a therapeutic radionuclide for RIT of prostate cancer (Figure 4.2). 
 
Figure 4.2: Schematic of RIT using radiolabeled A11 Mb. A, A11 Mb targets PSCA-positive 
prostate cancer cells, and the beta-emission from 131I or 177Lu reaches throughout the tumor 
and causes cytotoxic effects, including DNA and ROS damage. B, A11 Mb is radiolabeled 
with 124I for PET imaging and 131I for RIT. A11 Mb is conjugated to SCN-DFO or p-SCN-Bn-
CHX-A”-DTPA for 89Zr and 177Lu radiolabeling, respectively. 
 
Beta-emitters have several characteristics that may be beneficial for RIT of solid tumors 
including the ability to kill neighboring tumor cells by bystander effect. The beta-emitters 
iodine-131 (131I, t1/2 = 8.0 d) and lutetium-177 (177Lu, t1/2 = 6.7 d) offer different properties that 
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can affect the therapeutic index. The metabolites from conventionally radioiodinated probes 
diffuse from cells radiometal chelate metabolites retained in tumor cells, which results in 
lower off-target dose. On the other hand, radiometal chelate metabolites are retained in the 
cells of not only the tumor, but also healthy tissues. Therefore, comparison of the dosimetry 
of A11 Mb radiolabeled with either beta-emitter can help optimize therapeutic efficacy. 
 
In this study, we evaluated anti-PSCA A11 minibody radiolabeled with 131I or 177Lu for 
radioimmunotherapy of prostate cancer. 124I- and 89Zr-A11 Mb immunoPET imaging and 
quantification was used to profile the pharmacokinetics of 131I- and 177Lu-A11 Mb, 
respectively. 131I- and 177Lu-A11 Mb ex vivo biodistributions were used to calculate dosimetry 
and select which radionuclide to proceed with in the therapy studies. 131I-A11 Mb RIT was 
evaluated using mice bearing PSCA-positive s.c. tumors. Lastly, human-PSCA transgenic 
mice were used to evaluate 131I-A11 Mb uptake in normal tissue.  
 
4.2 Methods 
4.2.1 Cell Lines and Tumor Models 
To establish s.c. tumors, 0.5-1x106 22Rv1-PSCA cells in 1:1 Hank’s Buffered Saline Solution 
(Sigma):Matrigel (BD Bioscience) were implanted in the shoulder of 8- to 10-week-old male 
nu/nu mice (Foxn1nu, Jackson Laboratories), and tumors were allowed to grow for 10-14 
days. Mice were administered 131I-A11 Mb treatment when tumors were 100-200 mm3. 
Human PSCA knock-in (hPSCA-KI) C57BL/6J mice (18- to 27-week-old male and female) 
were bred at UCLA (57). Protocols for all animal studies were approved by the UCLA Animal 
Research Committee. 
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4.2.2 Conjugations 
A11 Mb was conjugated with p-isothiocyanatobenzyl-deferoxamine (p-SCN-Bn-DFO, B-705, 
Macrocyclics) to produce A11 Mb-DFO for 89Zr radiolabeling (108) as previously described 
(41). 
 
A11 Mb (97,98) was conjugated with the metal chelator 2-(p-isothiocyanatophenyl)-
cyclohexl-diethylenetriaminepentaacetic acid (p-SCN-Bn-CHX-A”-DTPA, B-355, 
Macrocyclics) to produce A11 Mb-DTPA for 177Lu-radiolabeling. In a typical reaction under 
metal-free conditions, A11 Mb (50 µl at 4 mg/ml) was incubated with 3-fold molar excess p-
SCN-Bn-CHX-A”-DTPA, and the reaction was immediately adjusted to pH 9 using 0.1 M 
sodium bicarbonate (1/10 volume). The reaction was allowed to proceed for 1 hour at room 
temperature, and excess p-SCN-Bn-CHX-A”-DTPA was removed using Micro Bio-Spin™ 
Size Exclusion Columns (Bio-Rad). A11 Mb-DTPA was dialyzed in 0.25 M ammonium 
acetate (NH4OAc) pH 5.5 and 5 g/L Chelex 100 (Bio-Rad).  
 
4.2.3 Radiolabeling 
Radiolabeling with 89Zr and 124I for imaging studies was conducted as previously described 
(41). Briefly, in a typical reaction, 100 µg of A11 Mb-DFO was incubated with 500 µCi (18.5 
MBq) 89Zr (3D Imaging LLC), or A11 Mb with 124I (3D Imaging LLC) using conventional 
iodination methods in Iodogen tubes (Pierce). 
 
 
Figure 4.3: Schematic of DTPA conjugation and 177Lu radiolabeling. 
 
+ 177Lu in 0.25 M NH4OAc
pH 5.5, 1 h, 37C
177Lu
177Lu
3x p-SCN-Bn-CHX-A”-DTPA
1 h, RT
– Lysine –DTPA
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 177Lu-A11 Mb was prepared similar to previous protocols (124). 177LuCl3 was supplied by the 
Isotope Program within the Office of Nuclear Physics in the Department of Energy’s Office of 
Science. The 177LuCl3 was buffered in 250 nM NH4OAc pH 5 (2x volume of 177LuCl3). In a 
typical reaction, 50 µg A11 Mb-DTPA was incubated with 0.5 mCi (18.5 MBq) 177Lu for 1 h at 
37ºC (Figure 4.3). The reaction was quenched with 0.25 M NH4OAc/acetic acid pH 5.5/50 
mM EDTA (0.1x volume of A11 Mb-DTPA + 177Lu) for 10 minutes.  
 
 
Figure 4.4: Schematic of 131I-A11 Mb radiolabeling. 
 
131I-A11 Mb was prepared using pre-coated Iodogen tubes according to the manufacturer’s 
instructions (Pierce). In a typical reaction, 200 µg of A11 Mb was incubated with 4-10 mCi 
(148-370 MBq) Na-131I (3D Imaging LLC) in 0.1 M Tris, pH 8.0 for 15 min at room 
temperature (Figure 4.4). For the cell cytotoxicity assay, 60 µg 131I-isotype control minibody 
(anti-CD20 GA101 cMb (125)) was radiolabeled with 600 µCi (22.2 MBq) Na-131I using the 
same conditions.  
 
Radiolabeled proteins were purified by size exclusion spin columns as previously described 
(61). Radiolabeling efficiency and radiochemical purity were assessed by Instant Thin Layer 
Chromatography (ITLC strips for radiolabeled antibodies, Biodex Medical System) with 20 
mM citrate pH 5.0 (89Zr-A11 Mb), 0.25 M NH4OAc/acetic acid pH 5.5/50 mM EDTA (177Lu-
A11 Mb), or saline (radioiodinated proteins) as solvent. The strips were analyzed by gamma 
counting (Wizard 3” 1480 Automatic Gamma Counter, Perkin-Elmer).  
 
The stability of 131I- and 177Lu-A11 Mb was tested by incubation in mouse serum (Sigma) at 
37ºC, and assessing the radiochemical purity at 4-24 hours by ITLC. Immunoreactivity was 
131I
131I
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completed as previously described (61) using 22Rv1-PSCA and 22Rv1 control cells 
immediately after radiolabeling, and at 24 and 72-96 hours. 
 
4.2.4 Cell cytotoxicity assay 
22Rv1-PSCA and 22Rv1 cells (1x104 cells) per well were plated in 96-well plates in 200 µl 
RPMI and incubated for 24 hours. 5 µCi (0.19 MBq) (1 µg protein) of 131I-A11 Mb, 131I-GA101 
cMb, 177Lu-A11 Mb, and unlabeled A11 Mb were added in triplicate with wells staggered to 
minimize potential cross-fire (maximum radioisotope path length ~ 2 mm). At 48 h, 72 h, and 
192 h, cells were assessed by crystal violet assay (OD at 550 nm). Percent cytotoxicity was 
calculated by (ODcontrol-ODsample)/ ODcontrol x 100%, ODcontrol = wells without treatment.  
 
4.2.5 PET/CT imaging 
In order to block nonspecific radioiodine uptake in thyroid and stomach, mice were given 
Lugol potassium iodide solution (Sigma-Aldrich) and potassium perchlorate (Sigma-Aldrich). 
124I or 89Zr radiolabeled A11 Mb (40-50 µCi, 1.5-1.9 MBq, 20 µg) in 0.1 mL saline was 
injected via tail vein (n=3). Immediately after injection, one mouse was anesthetized with 
1.5% isoflurane and a 2 h dynamic scan (1 frame x 60s interval, 3 x 180s, 4 x 300s, 9 x 
600s) was acquired using the G8 microPET scanner (Perkin Elmer), followed by a 1 min 
microCT scan (CrumpCAT). 10-min static scans were acquired at 4 h, 8 h, 24 h, 48 h, and 
72 h (n=3). 3D PET reconstruction was based on the Maximum Likelihood Estimation 
Method (MLEM) algorithm and AMIDE (113) was used for ROI analysis and image display. 
 
4.2.6 Biodistribution 
131I- or 177Lu-A11 Mb (10-18 µCi, 0.37-0.67 MBq, 1 µg + 9 µg cold A11 Mb) in 0.1 mL saline 
was injected via tail vein into 22Rv1-PSCA tumor-bearing male nude mice, or non-tumor-
bearing male and female hPSCA mice. At various time points (30 min, 2 h, 4 h, 8 h, 24 h, 48 
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h, 72 h, and 144 h; n=4 per time point), mice were terminated and blood and organs were 
collected, weighed, and gamma-counted for ex vivo biodistributions. Bone marrow was 
collected by flushing the femur with 200 µl PBS, and the sample was spun at 10,000 g for 5 
min. The total activity in the organ represented as percentage of injected dose per organ 
(%ID), and activity concentration represented as %ID per gram of tissue (%ID/g), were 
calculated based on a standard of 1% ID. 
 
4.2.7 Dose estimation 
The non-linear two phase decay equation y=m1*e-m2*x+m3*e-m4*x was used to fit the 
biodistribution data and determine the values for m1= kslow, m2=tauslow, m3=kfast, and 
m4=taufast, where x=time, k=rate constant, tau=time constant. Calculations were performed 
using GraphPad Prism (version 7.0a for Mac OS X, GraphPad Software). For each organ, 
the area under the curve (AUC, %ID*h) was calculated from the equation AUC = 
m1/(m2+λ)+m4/(m3+λ), using the decay constant λ=ln(2)/t1/2. The time-integrated activity 
coefficient (TIAC, h) also referred to in the literature as residence time) was calculated from 
TIAC=AUC*100%. The TIAC and mouse S-values (126) were used to determine the dose 
rate (Gy/MBq) for each organ. The dose-limiting organs and maximum administered activity 
for each radionuclide was determined by the maximum tolerated dose (Gy) for key organs 
based on literature (77), with the assumption the values are similar between human and 
mice. This assumption was made for a more conservative dose estimation, as mice have 
been shown to tolerate higher dose to key organs, including kidney, compared to humans 
(127). The dose to tumor was calculated using the sphere modeling program in 
OLINDA/EXM (128).  
 
4.2.8 Radioimmunotherapy 
Mice bearing 22Rv1-PSCA s.c. tumors (100-200 mm3 on day 0) were administered 1 mCi 
(37 MBq) (n=9), 300 µCi (11.1 MBq) (n=9), or 100 µCi (3.7 MBq) (n=9) 131I-A11 Mb (20 µg 
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protein dose), or saline (n=5). Mouse weight and tumor size (measured bi-directionally) were 
recorded every other day in the control and low administrated activity groups, and every day 
in the 1 mCi groups. Tumor size (mm3) was calculated as (length x width x width)/2. Mice 
were sacrificed if body weight decreased more than 15-20% of the original weight. For the 
tumor growth endpoint, mice were sacrificed when tumors reached ≥1000 mm3, and tumors 
were weighed at the end of the study. 
 
4.2.9 Tissue Analysis 
Blood samples (n=3 per group) were collected at termination for whole blood count analysis, 
which was performed by the UCLA Division of Laboratory Animals Medicine. Serum samples 
for 1 mCi 131I-A11 Mb group (n=3) were prepared at termination for biochemical analysis to 
assess potential acute toxicity to the liver (alkaline phosphatase, ALP) and kidney (blood 
urea nitrogen, BUN, and creatine, CRE). BUN levels correlate with the degree of radiation-
induced toxicity as seen by histopathology and is also predictive of eventual renal failure, 
and CRE is a marker of glomerular filtration rate, the preferred assay for renal injury in 
humans (127); therefore, both are good markers for radioimmunotherapy toxicity to the 
kidneys. 
 
Immunohistochemistry (IHC) was performed by the UCLA Translational Pathology Core 
Laboratory (TPCL) to stain samples for gamma H2AX (Phospho-Histone H2A.X Antibody, 
Thermo Fisher), as well as PSCA (EK5 antibody, UCLA TPCL). 
 
4.2.10 Statistics 
To estimate the interaction between radionuclide (131I, 177Lu) and biodistribution by time 
(%ID/organ for blood, tumor, kidney, liver), repeated measures ANOVA with Geisser-
Greenhouse correction and a significance threshold set to 0.05 was performed using 
Graphpad Prism (version 8). For statistical analysis of biodistribution area under the curve, 
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as well as cell cytotoxicity, multiple Student’s t-tests in Prism were performed with the 
significance threshold was set at 0.05, and P-values were corrected using the Holm–Šidák 
method.  
 
A linear mixed model with Type III tests of fixed effects was used to estimate the interaction 
of tumor growth and therapy group (100 µCi, 300 µCi, 1 mCi, saline) (IBM SPSS Version 24, 
2016). This test was completed with the help from the UCLA Statistical Consulting Group. 
Survival curves were displayed using the survival table format in Prism, median survival was 
calculated using the program’s built in survival curve analysis, and the log-rank (Mantel-Cox) 
test was used for survival curve comparison. Values in the tables are reported as mean +/- 
standard deviation.  
 
4.3 Results 
4.3.1 124I-A11 Mb and 89Zr-A11 Mb serial immunoPET/CT quantification 
Serial immunoPET imaging was used to evaluate the kinetics and biodistribution of A11 Mb. 
Therefore, the positron emitters 124I-A11 Mb and 89Zr-A11 Mb were used as surrogates for 
the therapeutic radionuclides 131I and 177Lu, respectively. Figure 4.5 displays representative 
time series of non-tumor-bearing mice (0-72 h post-injection, p.i.) injected with 124I-A11 Mb 
(Figure 4.5A) and 89Zr-A11 Mb (Figure 4.5B). As expected, while 124I-A11 Mb (non-
residualizing) cleared from blood, liver, and kidney by 24-48 h p.i., 89Zr-A11 Mb (residualizing 
radiometal) resulted in retention of activity in the kidneys (radiosensitive) and liver at 72 h.  
The 72 h ex vivo biodistribution confirmed high activity in organs of clearance, and an 
additional time point (144 h p.i.) was added for the subsequent biodistribution study. 
These results were confirmed by ROI quantification of the heart (representative of blood), 
liver, and kidney (Figure 4.6A). In mice administered 89Zr-A11 Mb, the kidney %ID/g 
calculated from ROI quantification differed from biodistribution results at 72 h, likely due to 
partial volume effect (Figure 4.6B).  
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Figure 4.5: Serial immunoPET/CT of non-tumor-bearing mice. A, 124I-A11 Mb (n=3) PET/CT 
images show whole body and bladder activity clears by 24-48 h (little to no activity seen at 
72 h, B, 89Zr-A11 Mb PET/CT images (n=3) show activity clears from blood pool by 24 h, and 
clearance to kidney (K) and liver (L) results in high activity even at 72 h. 
 
Figure 4.6: Quantification of 124I- and 89Zr-A11 Mb immunoPET/CT of non-tumor-bearing 
mice. A, 124I-A11 Mb ROI analysis confirms activity clears from the blood and organs by 24 
hours. For the 72 h data points, %ID/g calculated from ex vivo biodistribution for heart, liver, 
and kidney, was plotted due to activity clearance and inability to quantify from ROIs. B, 89Zr-
A11 Mb ROI analysis show high activity in the organs of clearance, liver and kidneys, at 72 
hours. At 72 h, the kidney %ID/g from ex vivo biodistribution is higher than calculated from 
ROI, likely due to partial volume effect. ROI analysis was done by averaging %ID/g from 3 
spheres placed in the heart and each kidney, and 6 spheres in the liver. 
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4.3.2 131I- and 177Lu-A11 Mb radiolabeling 
Radiolabeling with 131I and 177Lu was optimized in order to achieve high specific activity and 
maintain immunoreactivity (Table 4.1, Table 4.2). 131I-A11 Mb with a specific activity (SA) of 
4 µCi/µg (0.15 MBq/µg), typical for imaging studies, was used as a baseline comparison. 
131I-A11 Mb with SA of 17 µCi/µg (0.63 MBq/µg) had high radiolabeling efficiency (Table 
4.3), maintained radiolabeling stability (94%) at 24 h, and retained immunoreactivity (IR) 
(52%) similar to 131I-A11 Mb with SA of 4 µCi/µg (0.15 MBq/µg) at 72 h. In contrast, 131I-A11 
Mb with SA of 48 µCi/µg (1.8 MBq/µg) had slightly impaired IR (42%). Therefore, a target SA 
of 15-20 µCi/µg (0.56-0.74 MBq/µg) was used for low administered activity therapy groups, 
and a target SA of 50 µCi/µg (1.9 MBq/µg) was used for the 1 mCi (37 MBq) groups. 
 
The highest specific activity achieved for 177Lu-A11 Mb from testing radiolabeling ratios of 5, 
10, 20, and 50 µCi/µg (0.19, 0.37, 0.74, 1.85 MBq/µg) was 13 µCi/µg (0.48 MBq/µg). 177Lu-
A11 Mb with specific activity of 9.8 µCi/µg (0.36 MBq/µg) retained stability at 96 hours 
(93%), and immunoreactivity at 4 h (52%) (Table 4.2 need to add). Therefore, a radiolabeling 
ratio of 10 µCi/µg (0.37 MBq/µg) was used in the 177Lu-A11 Mb biodistribution study. 
 
 A B C 
Starting Activity 5 µCi/µg 20 µCi/µg 50 µCi/µg 
Specific Activity 4 µCi/µg 17 µCi/µg 48 µCi/µg 
Radiolabeling Efficiency 93% 92% 91% 
Bound Activity 4 h 92% 95% 94% 
Bound Activity 24 h 91% 94% 93% 
Immunoreactivity 4 h 66% 68% 61% 
Immunoreactivity 24 h 56% 58% 44% 
Immunoreactivity 72 h 56% 58% 48% 
 
Table 4.1: 131I-A11 Mb radiolabeling optimization. Comparison of samples A-C with 
increasing starting activities showed high radiolabeling efficiency and high retention of bound 
Chapter 4: Radioimmunotherapy of PSCA-positive prostate cancer 
    75 
activity at 24 h for all samples. Sample C showed a slight decrease in immunoreactivity (30 
mi 22Rv1-PSCA) at 24 and 72 h. Therefore, the ideal target specific activity of 131I-A11 Mb is 
20 µCi/µg to maximize the amount of activity delivered without compromising 
immunoreactivity. 
 
 A B C D 
Starting Activity 5 µCi/µg 10 µCi/µg 20 µCi/µg 50 µCi/µg 
Specific Activity 4.9 µCi/µg 9.8 µCi/µg 12 µCi/µg 13 µCi/µg 
Radiolabeling Efficiency  98% 98% 60% 27% 
Radiochemical Purity - - 98% 86% 
Bound Activity 24 h 94% 93% 97% 88% 
Bound Activity 96 h 93% 93% 96% 88% 
Immunoreactivity 4 h 48% 52% 57% - 
Table 4.2: 177Lu-A11 Mb radiolabeling optimization. Comparison of samples A-D with 
increasing starting activities showed high retention of incorporated activity at 96 h, and 
similar immunoreactivity (30 mi 22Rv1-PSCA) at 4 h. However, samples C and D had low 
radiolabeling efficiencies. Therefore, ~10 µCi/µg was the target specific activity of 177Lu-A11 
Mb used in following studies to retain bound activity and immunoreactivity. Future 
optimization of chelator conjugation ratios may allow for increased specific activity. 
 
 
 131I-A11 Mb 177Lu-A11 Mb 
Specific Activity 17 ± 3.5 µCi/µg 
n=6 
49 ± 2.7 µCi/µg 
n=5 
10 ± 1.6 µCi/µg 
n=3 
Radiolabeling 
Efficiency 
95 ± 2.5% 
n=6 
96 ± 2.6% 
n=5  
82 ± 20% 
n=3 
Radiochemical 
Purity 
>96% 
n=2 
99 ± 0.7% 
n=2 
>98%  
n=2 
Immunoreactivity  
(30 mi 22Rv1-
PSCA) 
58 ± 6.0% 
n=5 
53 ± 1.4% 
n=2 
55 ± 5.0% 
n=3 
Table 4.3: 131I- and 177Lu-A11 Mb radiolabeling and immunoreactivity from biodistribution and 
therapy studies. 
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4.3.3 Dose estimation based on 131I- and 177Lu-A11 Mb ex vivo biodistributions  
Dosimetry calculations for 131I- and 177Lu-A11 Mb were used to determine the optimal tumor-
to-normal tissue dose (therapeutic index). The ex vivo biodistribution data (Table 4.4, Table 
4.5) from 22Rv1-PSCA s.c. tumor-bearing nude mice was used to plot decay-corrected %ID 
time activity curves (Figure 4.7). The calculated tumor AUC was similar for 131I- and 177Lu-
A11 Mb. In contrast, the kidney AUC was greater for 177Lu-A11 Mb, and the maximum 
administered activity was calculated to be 200 µCi (7.4 MBq) based on previously published 
dose estimates (77) (tumor:kidney therapeutic index = 0.5, Table 4.6). For 131I-A11 Mb, the 
bone marrow was the dose-limiting tissue and the calculated maximum tolerated activity was 
1 mCi (37 MBq) (tumor:bone marrow therapeutic index = 22, Table 4.6). The dose delivered 
to 0.1 g tumor from administering 1 mCi 131I-A11 Mb or 200 µCi 177Lu-A11 Mb was estimated 
to be 35 Gy and 11 Gy, respectively. As 30-50 Gy is typically needed to effectively treat a 
radiosensitive tumor (77), 131I-A11 Mb was chosen for the subsequent in vivo RIT studies.  
 
 
Figure 4.7: Biodistribution time activity curves used for RIT dose estimation. A, 131I-A11 Mb 
and B, 177Lu-A11 Mb biodistributions in 22Rv1-PSCA s.c. tumor-bearing mice (n=4 per time 
point) show peak tumor uptake at 8 hours. As expected, high activity is retained in the liver 
and kidneys at 72 hours in mice injected with 177Lu-A11 Mb. There was a significant 
interaction between time and the radionuclide used on total organ activity for blood 
(F(7,42)=21.1, P<0.0001)), kidney (F(7,42)=27.9, P<0.0001)), and liver (F(7,42)=23.6, 
P<0.0001)), but no significant interaction for the tumor (F(7,41)=2.1, P=0.07)). The area 
under the curve for %ID/organ was used to calculate residence time and estimate dosimetry.  
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Table 4.4: 131I-A11 Mb biodistributions in 22Rv1-PSCA s.c. tumor-bearing nude mice (n = 4 per time point). Values are presented as total 
activity per organ (%ID ± standard deviation). Tumor:BM were not calculated for 48, 72, and 144 because %ID/BM was <10-3.  
  
  0.5 h 2 h 4 h 8 h 24 h 48 h 72 h 144 h 
AUC 
(%ID*h) 
Tumor 1.1 ± 0.3 1.1 ± 0.7 1.9 ± 1.3 2.5 ± 1.2 1.5 ± 1.0 0.9 ± 0.3 0.3 ± 0.2 0.0 ± 0.0 90 
Blood 12 ± 2.1 7.4 ± 0.9 4.7 ± 2.0 5.2 ± 0.1 0.4 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 100 
Kidney 2.2 ± 0.3 1.6 ± 0.2 0.9 ± 0.3 0.7 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 17 
Liver 3.8 ± 0.4 2.8 ± 0.6 1.8 ± 0.5 1.4 ± 0.1 0.2 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 31 
Stomach 1.3 ± 0.1 1.7 ± 0.2 1.3 ± 0.4 1.2 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 23 
Intestine 0.2 ± 0.0 0.4 ± 0.0 0.5 ± 0.2 0.4 ± 0.0 0.3 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 14 
Spleen 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 2.2 
Heart 0.5 ± 0.1 0.5 ± 0.1 0.3 ± 0.0 0.2 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 4.1 
Lung 0.8 ± 0.0 0.6 ± 0.1 0.4 ± 0.0 0.3 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 8.1 
Muscle 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.8 
Bone 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.8 
Bone marrow 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 
Ratios:          
Tumor:Blood 0.1 ± 0.04 0.2 ± 0.1 0.6 ± 0.6 0.5 ± 0.2 4.4 ± 13.7 18 ± 0.8 20 ± 10 32 ± 32 0.9 
Tumor:Kidney 0.6 ± 0.3 0.8 ± 0.6 2.3 ± 1.6 3.2 ± 1.6 13 ± 8.0 25 ± 9.6 21 ± 12 8.6 ± 6.7 5.2 
Tumor:BM 120 ± 90 130 ± 90 330 ± 240 380 ± 180 1400 ±1100    710 
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0.5 h 2 h 4 h 8 h 24 h 48 h 72 h 144 h 
AUC 
[%ID*h] 
Tumor 0.2 ± 0.1 1.0 ± 0.9 2.1 ± 0.4 1.1 ± 0.5 2.7 ± 1.7 0.8 ± 0.5 1.0 ± 0.7 0.5 ± 0.5 140 
Blood 22 ± 2.5 16 ± 2.3 9.2 ± 1.4 6.5 ± 1.2 1.0  ± 0.2 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 150 
Kidney 6.0 ± 1.1 7.7 ± 0.9 8.3 ± 1.3 9.9 ± 0.6 9.3 ± 0.6 7.2 ± 0.5 5.1 ± 0.5 2.5 ± 0.3 750 
Liver 5.7 ± 0.6 6.7 ± 0.8 8.3 ± 1.1 8.3 ± 0.6 7.3 ± 0.7 6.9 ± 0.4 5.4 ± 0.5 3.8 ± 0.5 850 
Stomach 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 20 
Intestine 1.9 ± 0.4 2.7 ± 0.2 3.2 ± 0.4 3.2 ± 0.5 2.4 ± 0.1 1.5 ± 0.1 1.1 ± 0.0 0.5 ± 0.0 180 
Spleen 0.3 ± 0.0 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 40 
Heart 0.9 ± 0.2 0.7 ± 0.1 0.6 ± 0.1 0.4 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.1 ± .0 0.0 ± 0.0 30 
Lung 1.1 ± 0.1 1.0 ± 0.2 0.8 ± 0.2 0.6 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 30 
Muscle 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.2 0.0 ± 0.3 0.0 ± 0.4 0.0 ± 0.5 0.0 ± 0.6 4.5 
Bone 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 9.8 
Bone Marrow 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 2.3 
Ratios:          
Tumor:Blood 0.0 ± 0.0 0.1 ± 0.05 0.2 ± 0.04 0.1 ± 0.09 3.8 ± 1.3 5.6 ± 4.8 21 ± 15 95 ± 60 0.9 
Tumor:Kidney 0.0 ± 0.00 0.1 ± 0.1 0.3 ± 0.1 0.1 ± 0.07 0.4 ± 0.1 0.1 ± 0.09 0.2 ± 0.1 0.3 ± 0.2 0.2 
Tumor:BM 170 ± 120 270 ± 280 1300 ± 880 120 ± 110 340 ± 240 160 ± 140 68 ± 47 70 ± 58 60 
Table 4.5: 177Lu-A11 Mb biodistributions in 22Rv1-PSCA s.c. tumor-bearing nude mice (n = 4 per time point). Values are presented as total 
activity per organ (%ID ± standard deviation).
 131I-A11 Mb  (1 mCi)  177Lu- A11 Mb (200 µCi) 
 Dose Tumor:Organ  Dose Tumor:Organ 
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Tumor (0.1 g) 35 Gy -  11 Gy - 
Bone marrow 1.6 Gy 22  0.5 Gy 23 
Kidney 3.3 Gy 10  20 Gy 0.5 
Liver 0.6 Gy 58  2 Gy 5 
Lung 3.0 Gy 11  2 Gy 5 
Table 4.6: Comparison of radiation dose to tumor and organs from administering maximum 
tolerated activity of 177Lu-A11 Mb and 131I-A11 Mb. 
 
4.3.4 131I-A11 Mb in vitro cytotoxicity 
The ability of 131I-A11 Mb to kill tumor cells in an antigen-specific manner was determined by 
cell cytotoxicity assay (Figure 4.8). Therefore, 22Rv1-PSCA and 22Rv1 control cells were 
treated with 131I-A11 Mb, 177Lu-A11 Mb, or with the non-specific control 131I-anti-CD20 cMb 
and non-radioactive A11 Mb. Treatment with 131I- and 177Lu-A11 Mb resulted in higher cell 
death in PSCA+ cells (22Rv1-PSCA) compared to PSCA-negative cells and control 
antibodies at all time points (P<0.05). At 168 h, both treatments specifically reduced cell 
viability to 24%, compared with 80-100% viability for 131I-anti-CD20 cMb (81%), unlabeled 
A11 Mb (103%), and 131I-A11 Mb added to 22Rv1 control cells (82%). 
 
Figure 4.8: 131I-A11 Mb RIT induces cell death. In an in vitro cell cytotoxicity assay, 5 µCi 
131I-A11 Mb treatments result in 24% viability of PSCA-positive cells at 168 h, compared to 
little to no inhibition of tumor cell growth in 131I-nonspecific Mb (P<0.001) and unlabeled A11 
Mb control groups (P<0.001), as well as 131I-A11 Mb added to PSCA-negative cells 
(P<0.001). 177Lu-A11 Mb treatment had similar results. 
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4.3.5 131I-A11 Mb RIT therapeutic effect 
131I-A11 Mb was evaluated in 22Rv1-PSCA s.c. tumor-bearing mice for effects on tumor 
growth and survival. In a dose escalation study, low (100 µCi and 300 µCi) and maximum 
calculated maximum administered activities (1 mCi) were tested. 131I-A11 Mb inhibited 
tumor-growth in a dose-dependent manner, with significant effects in the 1 mCi group 
(Figure 4.9A). 131I-A11 Mb treatment also corresponded with extended median survival in the 
300 µCi (18 d) and 1 mCi (24 d) groups compared to control mice receiving PBS (12 d) 
(Figure 4.9B). The average tumor weight at time of sacrifice was similar for 100 µCi, 300 
µCi, and control groups (1069 ± 274 mg), and was not higher for the 1 mCi group (831 ± 165 
mg) (Figure 4.9C). The tumor from a mouse treated with 1 mCi and collected 48 h p.i. for 
IHC stained positively for γH2AX, a marker for DNA double-strand breaks, demonstrating 
RIT induces DNA damage at early time points (Figure 4.9D).  
 
 
 
Figure 4.9: 131I-A11 Mb RIT inhibits tumor growth and extends survival. A, A single dose of 
131I-A11 Mb delays tumor growth in a dose-dependent manner in 1 mCi (n=6), 300 µCi (n=8), 
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and 100 µCi (n=7) therapy groups compared to saline control (n=5). B, Survival curves of 
mice administered 1mCi (median=24 d) and 300 µCi 131I-A11 Mb (median=19) have 
significantly survival curves (P<0.001 for both) compared to saline (median=12 d) while 
nonsignificant effect is observed in 100 µCi group (P=0.07). C, Spider plots of mice show a 
trend that unlabeled A11 Mb (n=6) does not inhibit tumor growth compared to saline (n=2), 
and 1 mCi A11 Mb (n=4) may inhibit tumor growth more than 1 mCi control cMb (n=4). 
However, the sample size is too small to draw conclusions. (Note: starting tumor size in A,B 
are larger than in C, D and therefore the data cannot be compared). D, The survival curve of 
mice that received 1 mCi control cMb (median=25 d) was not significantly different than mice 
that received unlabeled A11 Mb (median=14 d) (P=0.09). Survival was not calculated in the 
saline or 1 mCi groups due to small sample size and widespread data, respectively. 
 
 
Figure 4.10: Final tumor weights and IHC. A, The average tumor weight at the time of 
sacrifice was 830 mg (1 mCi), 1050 mg (300 µCi), 1060 mg (100 µCi), and 940 mg (saline). 
This demonstrates the 1 mCi group did not have artificially extended survival due to 
sacrificing mice with tumors larger than other groups. B, Tumors excised from mice in the 1 
mCi group stained positively for gamma H2AX, a marker of DNA damage, as well as PSCA.  
 
4.3.6 131I-A11 Mb RIT toxicity 
131I-A11 Mb off-target toxicity was monitored by assessing mouse body weight throughout 
the therapy study, and assessing blood counts and biochemical levels representative of liver 
and kidney damage at time of sacrifice. Despite an initial drop in weight among all therapy 
and control groups in day 0-2, the majority of mice recovered by day 10 (Figure 4.11). 
However, one mouse in the 1 mCi group was terminated at day 10 due to continued weight 
loss and decrease in body conditioning score.  
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Figure 4.11: Mouse body weights over the course of therapy. Mice in all therapy groups 
experienced weight loss at day 0-2, and the majority recovered by day 10. However, one 
mouse in the 1 mCi group was sacrificed due to a decrease in body conditioning score and 
weight loss of 20% of the original body weight. 
 
Blood counts were not significantly different between control and therapy groups (P>0.05) 
(Figure 4.12A). Biochemicals representative of damage to the liver (alkaline phosphatase, 
alanine aminotransferase) and kidney (blood urea nitrogen, creatine) were not higher in mice 
receiving 1 mCi 131I-A11 Mb (n=3) compared to mice that did not receive treatment (Figure 
4.12B).  
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Figure 4.12: Blood and serum biochemical analysis. A, Blood counts (white blood cells, 
WBC; neutrophils, NEU; lymphocytes, LYM; red blood cells, RBC) were not significantly 
different between the therapy groups at time of sacrifice (P>0.05). However, a single mouse 
from the 1 mCi group that was sacrificed due to decreased weight and body conditioning 
score had significantly higher lymphocytes (reasons unknown and therefore data not 
shown). B, Serum analysis of mice treated with 1 mCi 131I-A11 Mb (n=3) did not show 
increase in biochemicals representative of liver (alanine transferase, ALT) and kidney 
damage (blood urea nitrogen, BUN; creatine, CRE) compared with reported values for nude 
mice from Charles River. 
 
4.3.7 131I-A11 Mb biodistributions in hPSCA mice 
131I-A11 Mb biodistributions were completed in hPSCA transgenic mice in order to evaluate if 
the expression of hPSCA in background tissues, including stomach, prostate, and bladder, 
would alter the dosimetry calculations or lead to toxicity. Comparison of biodistributions of 
male hPSCA mice at 2 h, 4 h, 8 h, 24 h, and 48 h and of female hPSCA mice at 8 h (Table 
4.7) with the time activity curves from nude mice (Figure 4.13) suggests normal PSCA 
expression would not alter the dosimetry estimation of 131I-A11 Mb RIT. Comparing male 
hPSCA mice (n=4) and male nude mice, a significant interaction was observed between 
mouse type and time on stomach %ID (Table 4.4), but the %ID in hPSCA mice was actually 
lower, likely due to more complete radioiodine blockage. Therefore, radioimmunotherapy in 
the more relevant hPSCA model likely will not result in increased dose to stomach or 
bladder.  
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Dosimetry estimation models differ between human males and females, as females typically 
have smaller organs and toxicity to the ovaries is a potential concern due to proximity to  
source organs such as kidney and bladder (129). Therefore, one group of female hPSCA 
mice were also administered 131I-A11 Mb and biodistribution was analyzed at 8 h. No 
significant difference was observed between the biodistribution of male and female hPSCA 
mice, and therefore radioimmunotherapy in other PSCA cancer models (pancreatic, bladder) 
will likely not result in increased dose to organs in female mice. However, future studies will 
need to include a more complete biodistribution in order to calculate dosimetry based on the 
correct mouse weight and use a model that includes the ovaries.
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 2 h 4 h 8 h 8 h female 24 h 48 h 
 n = 4 n = 4 n = 4 n = 3 n = 4 n = 3 
Blood 5.9 ± 0.7 4.7 ± 0.8 3.5 ± 0.3 2.5 ± 0.3 0.6 ± 0.1 0.1 ± 0.04 
Stomach 0.4  ± 0.1 0.4 ± 0.02 0.6 ± 0.1 0.4 ± 0.03 0.3 ± 0.1 0.1 ± 0.02 
Liver 2.1 ± 0.2 1.9 ± 0.1 1.4 ± 0.2 0.8 ± 0.1 0.3 ± 0.02 0.1 ± 0.02 
Large intestine 0.7 ± 0.4 0.7 ± 0.2 0.7 ± 0.1 0.5 ± 0.1 0.2 ± 0.02 0.03 ± 0.0 
Small intestine 1.6 ± 0.4 1.7 ± 0.2 1.2 ± 0.02 1.0 ± 0.1 0.3 ± 0.02 0.04 ± 0.02 
Kidney 1.2 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.5 ± 0.03 0.1 ± 0.05 0.03 ± 0.01 
Spleen 0.2 ± 0.02 0.14 ± 0.01 0.1 ± 0.01 0.1 ± 0.01 0.02 ± 0.0 0.0 ± 0.0 
Pancreas 0.2 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.1 ± 0.01 0.02 ± 0.01 0.0 ± 0.0 
Heart 0.6 ± 0.1 0.5 ± 0.2 0.3 ± 0.1 0.2 ± 0.1 0.06 ± 0.01 0.0 ± 0.0 
Lung 0.1 ± 0.01 0.6 ± 0.1 0.5 ± 0.1 0.3 ± 0.1 0.1 ± 0.01 0.01 ± 0.0 
Prostate/ovaries 0.1 ± 0.02 0.2 ± 0.1 0.2 ± 0.1 0.03 ± 0.01 0.04 ± 0.01 0.0 ± 0.0 
Seminal vesicle 0.2 ± 0.1 0.3 ± 0.2 0.1 ± 0.02 0.0 ± 0.0 0.04 ± 0.01 0.0 ± 0.0 
Bladder 0.1 ± 0.01 0.1 ± 0.02 0.1 ± 0.05 0.1 ± 0.04 0.03 ± 0.01 0.0 ± 0.0 
Muscle 0.04 ± 0.01 0.1 ± 0.02 0.1 ± 0.0 0.04 ± 0.01 0.01 ± 0.0 0.0 ± 0.0 
Bone 1.5 ± 0.5 0.04 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.01 ± 0.0 0.0 ± 0.0 
Bone marrow 0.002 ± 0.0 0.001 ± 0.0 0.002 ± 0.0 0.001 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
Table 4.7: 131I-A11 Mb biodistributions in non-tumor-bearing hPSCA transgenic mice. A significant interaction (P<0.0001) was observed 
between time and mouse type (male hPSCA and male nude, Table 4.4) on %ID of stomach (PSCA-positive in hPSCA mice), while there was 
not a significant interaction (P>0.05) for blood, liver, and kidney. Additionally, there was not a significant difference between male and female 
biodistributions at 8 h. Values are presented as %ID ± standard deviation. 
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Figure 4.13: 131I-A11 Mb biodistribution of male non-tumor-bearing hPSCA mice. Ex vivo 
biodistributions of hPSCA mice at 2, 4, 8, 24, and 48 h (squares and solid lines) p.i. did not 
show an increase in %ID of PSCA-positive stomach at any time point (see Table 4.7), nor 
blood, kidney, or liver (P>0.05) compared nude mice (circles and dotted lines). Therefore, 
the dose estimation for 131I-A11 Mb RIT is likely similar to that of nude mice without 
increased dose or toxicity to the stomach. 
 
4.4 Discussion 
Prostate cancer treatments such as androgen deprivation therapy can extend the life of 
patients with mCRPC, yet the disease ultimately progresses and becomes resistant. 
Radioimmunotherapy is a promising alternative (79), and the goal is to use antibodies to 
deliver cytotoxic radiation to the tumor and minimize normal tissue toxicity. However, a high 
radiation dose is required to treat solid tumors, and dosimetry must be performed to predict 
the corresponding dose to radiosensitive normal tissues including bone marrow and kidney 
(77). This balance depends on the agent’s clearance, binding affinity, metabolism, and the 
choice of radionuclide.  
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The anti-PSCA A11 minibody radiolabeled with 124I was previously used for immunoPET of 
prostate tumor models and successfully detected intratibial bone metastases, as well as 
response to anti-androgen therapy (42). Therefore, we propose beta-emitter-radiolabeled 
A11 Mb could be an effective radioimmunotherapy agent. In this study, 124I- and 89Zr-A11 Mb 
immunoPET were useful surrogates to profile the pharmacokinetics of radiolabeled A11 Mb. 
131I- and 177Lu-A11 Mb biodistributions were used in dosimetry calculations that predicted 
131I-A11 Mb would have a higher therapeutic index. Additionally, the maximum tolerated 
activity of 131I-A11 Mb of 1 mCi (37 MBq) was estimated to deliver a tumoricidal dose (35 
Gy), with bone marrow as the dose-limiting organ. 131I-A11 Mb dose escalation was 
performed in mice bearing PSCA-positive xenografts, and tumor growth was inhibited in a 
dose-dependent manner that translated to extended median survival.  
 
Compared to 131I (nonresidualizing when labeled by conventional methods), the beta-emitter 
177Lu (residualizing) has progressed further in the clinic as a successful RIT radiolabel for 
prostate cancer, likely because it can deliver a higher dose to the tumor. However, both 131I- 
and 177Lu-A11 Mb had similar cell-killing effects in vitro. When iodistribution dosimetry 
calculations were performed, the 177Lu-A11 Mb time activity curves showed unexpected 
clearance to the kidneys, and the corresponding therapeutic profile was not as promising as 
131I-A11 Mb. Although 131I-A11 Mb showed tumor inhibitory effects in vivo, 177Lu may be 
considered in future studies for increased dose to the tumor. 
 
Future studies include re-engineering the minibody, modifying the therapy regimen, and 
testing more relevant models. As the A11 Mb did not have the anticipated profile, it could be 
re-engineered to a larger fragment to shifts clearance to the liver, yet retains similarly fast 
pharmacokinetics compared to the intact antibody. Additionally, dose fractionation can allow 
for the delivery of a higher cumulative dose, and a Phase I study currently evaluating the 
efficacy of fractionated 177Lu-PSMA-617 (NCT03042468) may inform future studies using 
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anti-PSCA antibody fragments. Lastly, more relevant tumor models should be explored. A11 
Mb-IRDye800CW was successfully used to detect metastases in the hPSCA transgenic 
mouse model with normal expression of PSCA (57), and therefore this model would also be 
useful for RIT evaluation. In preliminary dosimetry studies, the normal expression of PSCA 
in hPSCA mice did not significantly affect the ex vivo biodistribution; therefore, 1 mCi 131I-
A11 Mb could also be tested in this mouse model without increased dose to stomach and 
bladder. 
 
Although other radioimmunotherapy agents have been evaluated for prostate cancer in 
several preclinical and clinical studies (79), none are curative. In a systematic review of 
clinical trials evaluating 177Lu-anti-PSMA antibodies and ligands, only 37% of patients 
responded with PSA decline (93). Additionally, using radiolabeled intact antibodies (long 
circulating half-life) can lead to higher bone marrow dose. Hematological toxicity was 
observed in all patients administered a single dose of 177Lu-J591 (intact antibody) (91). In 
contrast, small molecules (short circulating half-life) for RIT, such as 177Lu-PSMA-617 ligand, 
result in less hematological toxicity. However, other adverse events including xerostomia 
were observed in patients who received 177Lu-PSMA-617 (94), and some patients 
discontinued treatment due to such toxicity. Using an anti-PSCA minibody may address both 
toxicity issues, as it has a shorter half-life than intact antibodies and typically clears to the 
liver (radioresistant). Additionally, PSCA is not expressed on the salivary glands and is 
expressed at low levels on other radiosensitive organs (bone marrow, kidney), and it is a 
promising target for radioimmunotherapy.  
 
In addition to beta-radioimmunotherapy, there has been a recent surge in interest in alpha- 
radioimmunotherapy; the majority of studies have been focused on peptides, but the 
strategy can also be applied to the minibody.  Radiolabeling A11 Mb with an alpha-emitter, 
which has a short path length and high linear energy transfer, may increase therapeutic 
efficacy especially if the disease has metastasized (130). In one study, over 63% of mCRPC 
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patients responded to 225Ac-PSMA-617 salvage therapy, which was greater than the 
response rate in patients given 177Lu-PSMA-617 (76). However, 225Ac-PSMA-617-induced 
salivary gland toxicity was surprisingly similar to 177Lu-PSMA-617, potentially due to small-
molecule transporters rather than PSMA-expression (95). Using antibodies or antibody 
fragments may reduce off-target toxicity, and 225Ac-anti-PSMA antibody J591 is currently 
being evaluated in mCRPC patients in a Phase I trial (NCT03276572). 211At-A11 Mb 
administered in a fractionated regimen was shown to reduce the size of both subcutaneous 
(200 mm3) and intratibial tumors (100-200 µm) (manuscript in preparation, courtesy of Dr. 
Tom Bäck), and the results can inform future studies comparing the dosimetry and 
therapeutic effect with beta-RIT.  Additional combination therapies include using 
chemotherapy to radiosensitize the tumors before administering RIT, which has been shown 
to enhance the therapeutic effect in preclinical models (131). 
 
4.5 Conclusion 
Beta-emitter labeled A11 Mb was evaluated for radioimmunotherapy of PSCA-positive 
prostate cancer. 131I- and 177Lu dosimetry calculations showed 131I-A11 Mb could deliver a 
higher therapeutic dose while minimizing off-target effects. 131I-A11 Mb radioimmunotherapy 
successfully inhibited tumor growth and extended survival of mice with PSCA-positive s.c. 
xenografts with minimal toxicity. These results show anti-PSCA antibody fragments may be 
effective agents for prostate cancer radioimmunotherapy in the clinic. This work supports the 
potential of radiolabeled A11 Mb as a theranostic agent, where A11 Mb-based immunoPET 
could help stratify patients, inform dosimetry for personalized treatment, and monitor 
therapeutic efficacy, in addition to treating the patient potentially in combination with other 
therapies.  
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5 Conclusion 
In this dissertation, I used radiolabeled antibody fragments for dual-modality imaging and 
radioimmunotherapy of PSCA-positive prostate cancer. I dual-labeled the anti-PSCA A11 
cys-minibody with a positron emitter (124I or 89Zr) and near-infrared fluorophore (Cy5.5) and 
imaged PSCA-positive tumors by sequential immunoPET and fluorescence. 124I-A11 cMb-
Cy5.5 immunoPET was used to detect 22Rv1-PSCA (high expression) and PC3-PSCA 
(moderate expression) subcutaneous tumors with high contrast, and fluorescence signal 
was specific to PSCA-positive tumors. In addition, 89Zr-A11 cMb-Cy5.5 identified 
intraprostatic 22Rv1-PSCA tumors by immunoPET, and ex vivo fluorescence imaging 
delineated between the prostate and surrounding seminal vesicles. I also compared A11 
minibody radiolabeled with the beta-emitters 131I and 177Lu and determined 131I-A11 Mb had a 
higher therapeutic index. 131I-A11 Mb RIT caused dose-dependent tumor growth inhibition 
and extended survival of mice bearing 22Rv1-PSCA subcutaneous tumors. 
 
Positive prostate tumor margins are difficult to visualize during surgical resection, and over-
resection can damage surrounding healthy tissue and nerves while under-resection leads to 
disease recurrence. Combining the advantages of immunoPET and fluorescence onto a 
single agent can provide a preoperative whole-body image to confirm if the disease is 
localized to the prostate or has spread to regional lymph nodes, as well as a corresponding 
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fluorescent signal for intraoperative guidance to improve resection accuracy. Anti-PSMA 
agents have been evaluated for dual-modality imaging, yet PSMA expression in normal 
ganglia may confound lymph node staging, and PSMA is not expressed in 10% of patients. 
PSCA expression correlates with tumor grade and stage, and we showed dual-labeled A11 
cMb could detect both high PSCA and moderate PSCA subcutaneous tumors, indicating the 
potential utility of A11 cMb in different stages of prostate cancer. Dual-modality A11 cMb 
was also able to visualize intraprostatic tumors, demonstrating accessibility to the site of 
natural disease and supporting the potential for clinical translation. We believe dual-modality 
immunoPET/fluorescence can be used for noninvasive whole-body imaging and real-time 
intraoperative guidance in patients with PSCA-positive prostate cancer. 
 
The A11 minibody has the potential to be used as a theranostic agent to provide an image 
that confirms PSCA-overexpression and guides dosimetry estimation, and deliver cytotoxic 
radioactivity to treat the lesions by radioimmunotherapy. The radionuclide emission type 
(beta-emitter for larger lesions and alpha-emitter for small metastases) and pharmacokinetic 
properties (residualizing and non-residualizing) contributes to the therapeutic index. I found 
131I- and 177Lu-A11 Mb were both cytotoxic to PSCA-positive cells, but dosimetry estimation 
guided by immunoPET and calculated from biodistributions showed 131I-A11 Mb would have 
a higher tumor dose-to-radiosensitive organ dose ratio. As 131I-A11 Mb successfully inhibited 
growth of PSCA-positive tumors and extended survival, A11 Mb may be similarly effective 
when paired with an alpha-emitter to treat metastatic disease. Additionally, therapeutic 
effects may be enhanced by combining radioimmunotherapy with other therapies (ie 
immunotherapy, chemotherapy, alpha and beta emitters). Therefore, A11 Mb or another 
anti-PSCA fragment modified to clear to the liver may be a useful theranostic for prostate 
cancer patients.  
 
In conclusion, anti-PSCA minibody-based imaging prostate cancer can guide surgery, and 
radioimmunotherapy can be an effective treatment option to inhibit tumor growth and extend 
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survival. Dual-modality imaging may also be used to stratify patients before pursuing 
surgical resection, while radioimmunotherapy could have an enhanced effect in combination 
with other therapies. This theranostic approach could also be evaluated in other PSCA-
positive disease settings such as pancreatic cancer.  These studies support the continuation 
of immunoPET/fluorescence and radioimmunotherapy studies in the clinic. 
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6 Appendix 
The following appendix describes the dosimetry calculations for the radioimmunotherapy 
studies presented in Chapter 4. These calculations were completed in collaboration with Dr. 
Magnus Dahlbom at UCLA. More information on fundamental concepts for calculating 
radiation dose, as well as case studies, can be found in the book Fundamentals of Nuclear 
Medicine Dosimetry by Dr. Michael G. Stabin (132). 
 
6.1 Using biodistribution data to calculate TIAC 
This section will describe how to enter biodistribution data into Prism and plot time activity 
curves, which represents the total activity in the organ over time. The resulting values m1-
m4 (explained below) are used to calculate the area under the curve (AUC), which 
represents cumulative activity, and subsequently the time integrated activity coefficient 
(TIAC, previously known as residence time). The radionuclide decay constant (λ) is included 
in the AUC and TIAC calculations, which removes effect of physical decay and isolates the 
biological decay.  
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6.1.1 Time activity curve calculations  
1) In Prism, create XY table, format for replicates. Enter time (h) into X. Each organ is in 
separate column group (Group A, B, C). Enter %ID/organ. 
 
2) Analyze > Nonlinear Regression  
a. Model: Create new equation > Equation Type: Explicit Equation > Definition: 
Y=m1*exp(-m2*x)+m3(exp(-m4*x)  
i. m1 = amplitude or time constant (fast) 
ii. m2 = slope or uptake constant, (fast) 
iii. m3 = time constant (slow) 
iv. m4 = uptake constant (slow, <m2) 
v. x = independent variable, time 
b. Initial values: (nonlinear regression is iterative and must start with estimated 
values for each variable within factor of five of actual value)  
i. Blood fits exponential decay (two-phase model captures fast and slow 
decay): m1 = 5, m2 = 0.1, m3 = 10, m4 = 0.01  
ii. Uptake in tumor before washout: m1 = 5, m2 = 0.01, m3 = -10, m4 = 
0.1 
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3) Results Table: Best-fit values, std error, 95% CI, and goodness of fit for m1-m4 
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6.1.2 Time integrated activity coefficient (TIAC) calculations 
1) In excel, enter m1-m4 values for all organs from Prism 
2) AUC (%ID*h) = m1/m2+m3/m4 
3) AUC with decay constant = m1/(m2+λ)+m4/(m3+λ), λ = ln(2)/t1/2, t1/2 in hours 
a. λ for 131I = ln(2)/192.5 = 0.0036 
b. λ for 177Lu= ln(2)/161.5 = 0.0043 
4) TIAC = AUC (%ID*h) / (100%)  
5) TIAC-error = sqrt((sd1/m2)^2 + (sd2*m1/m2^2)^2 + (sd3/m4)^2 + (sd4*m3/m4^2)^2 ) 
/ (100%) 
 
 
6.2 Using S-values to calculate dose to organs 
This section will describe how to use S-values to calculate dose to organs using 131I-A11 Mb 
and the TIAC for bone marrow as an example. The 131I and 177Lu mouse S-values were 
kindly provided by Dr. Erik Larsson, calculated using the MOBY mouse phantom (126). For 
the full dataset please contact him at erik.larsson@med.lu.se and provide mouse weight and 
radionuclide. OLINDA version 1.1 was used for the dose to tumor calculations presented in 
chapter 4.  
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6.2.1 Dose to organ calculations 
1) Assumptions may need to be made for organs not collected in the biodistribution. For 
example, organs such as brain were omitted from the following calculations. The 
same residence time was used for intestine and intestine contents, as well as left and 
right lung, and left and right kidney. Additionally, the TIAC for femur bone was 
extrapolated to ribs, spine, and skull. 
 
2) Enter decay-corrected TIAC 
 
3) Multiply S-value x TIAC = Dose to target organ 
 
4) Sum up all doses = Total dose for organ, convert to Gy/µCi. 
5) Use literature to obtain maximum tolerated dose for the organ (77). Maximum 
tolerated activity = maximum dose/total dose. Based on this value, determine 
administered activities to test in the therapy study, and calculate the corresponding 
dose to organ. 
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6.2.2 Using OLINDA to calculate the tumor dose 
1) Input radionuclide, and enter TIAC of the s.c. tumor in spheres model input form. 
2) The results file will show the total dose (mGy/MBq) for a range of sphere masses. 
Use the total dose for the sphere mass of interest (i.e. 0.1 g) and calculate dose to 
tumor for corresponding administered activity groups by multiplying total dose and 
activity. 
 
3) To control the source and target organs used for the tumor dose calculation, tumor 
S-values can also be obtained from Dr. Erik Larsson. These values correspond to a 
MOBY phantom with four subcutaneous tumor placement options (data not shown). 
 
6.3 Dose calculation results from Chapter 4 
6.3.1 131I-A11 Mb dose to organ calculations  
Across a row, the summation of the values equal the total dose for the target organ. 
Maximum tolerated dose from the literature (77) was used to identify the dose-limiting organ. 
For 131I-A11 Mb , the bone marrow is the dose-limiting organ, as the maximum tolerated 
dose of 1.5 Gy corresponds to a maximum tolerated activity of 955 µCi, while the maximum 
tolerated activity for liver, lung and kidney is higher. 
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6.3.2 177Lu-A11 Mb dose to organs calculations 
For 177Lu-A11 Mb, the kidney is the dose-limiting organ, and the maximum tolerated dose of 20 Gy corresponds to a maximum tolerated activity 
of 180 µCi. 
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6.3.3 Radionuclide comparison 
 
The total dose to a 0.1 g was calculated in OLINDA. Administering the maximum tolerated 
activity for 131I-A11 Mb (1000 µCi) and 177Lu-A11 Mb (200 µCi) results in a 35 Gy and 11Gy 
dose delivered to a 0.1 g tumor, respectively. Therefore, 131I-A11 Mb was chosen for the 
subsequent in vivo therapy studies. 
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